USRE41920E1 - Isobutylgaba and its derivatives for the treatment of pain - Google Patents

Isobutylgaba and its derivatives for the treatment of pain Download PDF

Info

Publication number
USRE41920E1
USRE41920E1 US11/983,750 US98375097A USRE41920E US RE41920 E1 USRE41920 E1 US RE41920E1 US 98375097 A US98375097 A US 98375097A US RE41920 E USRE41920 E US RE41920E
Authority
US
United States
Prior art keywords
pain
treated
aminomethyl
paw
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US11/983,750
Inventor
Lakhbir Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21809080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE41920(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of USRE41920E1 publication Critical patent/USRE41920E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention is the use of analogs of glutamic acid and gamma-aminobutyric acid (GABA) in pain therapy, as the compounds exhibit analgesic/antihyperalgesic action.
  • GABA gamma-aminobutyric acid
  • Advantages of the use of the compounds includes the finding that repeated use does not lead to tolerance nor is there a cross-tolerance between morphine and the compounds.
  • the compounds of the invention are known agents useful in antiseizure therapy for central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischemia, Parkinson's disease, tardive dyskinesia, and spasticity. It has also been suggested that the compounds can be used as antidepressants, anxiolytics, and antipsychotics. See WO 92/09560 (U.S. Ser. No. 618,692 filed Nov. 27, 1990) and WP 93/23383 (U.S. Ser. No. 886,080 filed May 20, 1992).
  • the instant invention is a method of using a compound of Formula I below in the treatment of pain, especially for treatment of chronic pain disorders.
  • disorders include, but are not limited to, inflammatory pain, postoperative pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, bum burn pain, and other forms of neuralgic, neuropathic, and idiopathic pain syndromes.
  • a compound are those of Formula I or a pharmaceutically acceptable salt thereof wherein
  • Diastereomers and enantiomers of compounds of Formula I are included in the invention.
  • Preferred compounds of the invention are those according to claim 1 wherein R 3 and R 2 are hydrogen, and R 1 is —(CH 2 ) 0-2 —i C 4 H 9 as an (R), (S), or (R,S) isomer.
  • the more preferred compounds of the invention are (S)-3-(aminomethyl)-5-methylhexanoic acid and 3-aminomethyl-5-methyl-hexanoic acid.
  • FIG. 1 Effect of Gabapentin (1-(aminomethyl)-cyclohexaneacetic acid), CI-1008 ((S)-3-(aminomethyl)-5-methylhexanoic acid), and 3-aminomethyl-5-methylhexanoic acid in the Rat Paw Formalin Test
  • Test compounds were administered s.c. 1 hour before an intraplantar injection of 50 ⁇ L formalin. The time spent licking/biting the injected paw during the early and late phases was scored. Results are shown as the mean ⁇ SEM of 6 to 8 animals per group. *P ⁇ 0.05 and **P ⁇ 0.01 significantly different from vehicle (Veh.) treated controls (ANOVA followed by Dunnett's t-test).
  • FIG. 2 Effect of Gabapentin and CI-1008 on Carrageenin-Induced Mechanical Hyperalgesia
  • Nociceptive pressure thresholds were measured in the rat using the paw pressure test.
  • Baseline (BL) measurements were taken before animals were administered with 100 ⁇ L of 2% carrageenin by intraplantar injection. Results are shown as mean ( ⁇ SEM) of 8 animals per group.
  • Gabapentin (GP), CI-1008, or morphine (MOR; 3 mg/g) was administered s.c. 3.5 hours after carrageenin.
  • FIG. 3 Effect of Gabapentin and CI-1008 on Carrageenin-Induced Thermal Hyperalgesia
  • Nociceptive thermal thresholds were measured in the rat using the Hargreaves apparatus.
  • Baseline (BL) measurements were taken before animal s were administered with 100 ⁇ L of 2% carrageenin by intraplantar injection. Results are shown as mean ( ⁇ SEM) of 8 animals per group.
  • Gabapentin (GP) or CI-1008 was administered s.c. 2.5 hours after carrageenin. *P ⁇ 0.05 and **P ⁇ 0.01 significantly different from vehicle control group at the same time point (ANOVA followed by Dunnett's t-test).
  • FIG. 4 Effect of (a) Morphine, (b) Gabapentin, and (c) S-(+)-3-Isobutylgaba on Thermal Hyperalgesia in the Rat Postoperative Pain Model
  • Gabapentin or S-(+)-3 isobutylgaba was administered 1 hour before surgery. Morphine was administered 0.5 hour before surgery.
  • Thermal paw withdrawal latencies (PWL) were determined for both ipsilateral and contralateral paws using the rat plantar test. For clarity contralateral paw data for drug-treated animals is not shown.
  • Baseline (BL) measurements were taken before surgery and PWL were reassessed 2, 24, 48, and 72 hours postsurgery. Results are expressed as the mean PWL(s) of 8 to 10 animals per group (vertical bars represent ⁇ SEM).
  • FIG. 5 Effect of (a) Morphine, (b) Gabapentin, and (c) S-(+)-3-Isobutylgaba on Tactile Allodynia in the Rat Post-operative Pain Model
  • Gabapentin or S-(+)-3-isobutylgaba was administered 1 hour before surgery. Morphine was administered 0.5 hour before surgery. Paw withdrawal thresholds to von Frey hair filaments were determined for both ipsilateral and contralateral paws. For clarity, contralateral paw data for drug-treated animals is not shown. Baseline (BL) measurements were taken before surgery, and withdrawal thresholds were reassessed 3, 25, 49, and 73 hours postsurgery. Results are expressed as median force (g) required to induce a withdrawal of paw in 8 to 10 animals per group (vertical bars represent first and third quartiles).
  • — ⁇ — is 3 mg/kg, — ⁇ — is 10, and — ⁇ — is 30.
  • FIG. 6 Effect of S-(+)-3-Isobulylgaba on the Maintenance of (a) Thermal Hyperalgesia and (b) Tactile Allodynia in the Rat Postoperative Pain Model.
  • S-(+)-3-Isobutylgaba (S-(+)-IBG) was administered 1 hour after surgery.
  • Thermal paw withdrawal latencies determined using the rat plantar test, and paw withdrawal thresholds to von Frey hair filaments, were determined in separate groups of animals for both ipsilateral and contralateral paws. For clarity only the ipsilateral paw data is shown.
  • Baseline (BL) measurements were taken before surgery and withdrawal thresholds were reassessed up to 6 hours postsurgery.
  • the results are expressed as the mean PWL(s) of 6 animals per group (vertical bars represent ⁇ SEM), *P ⁇ 0.05 **P ⁇ 0.01 significantly different (unpaired t-test), comparing ipsilateral paw of drug-treated group to ipsilateral paw of vehicle (Veh — ⁇ —) treated group at each time point.
  • the results are expressed as median force (g) required to induce a paw withdrawal of 6 animals per group (vertical bars represent first and third quartiles). *P ⁇ 0.05 significantly different (Mann Whitney t-test), comparing ipsilateral paw of drug-treated group to ipsilateral paw of vehicle-treated group at each time point.
  • — ⁇ — is S-(+)-IBG at 30 mg/kg.
  • the instant invention is a method of using a compound of Formula I above as an analgesic in the treatment of pain as listed above.
  • Pain such as inflammatory pain, neuropathic pain, cancer pain, postoperative pain, and idiopathic pain which is pain of unknown origin, for example, phantom limb pain are included especially.
  • Neuropathic pain is caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis.
  • Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies.
  • Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from.
  • analgesics such as narcotics or nonsteroidal anti-inflammatory drugs (NSAID) due to insufficient efficacy or limiting side effects.
  • NSAID nonsteroidal anti-inflammatory drugs
  • alkyl which term is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, isopentyl, and neopentyl, as well as those as would occur to one skilled in the art.
  • cycloalkyl is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • the compounds of the present invention may form pharmaceutically acceptable salts with both organic and inorganic acids or bases.
  • the acid addition salts of the basic compounds are prepared either by dissolving the free base in aqueous or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution.
  • pharmaceutically acceptable salts are hydrochlorides, hydrobromides, hydrosulfates, etc. as well as sodium, potassium, and magnesium, etc. salts.
  • the compounds of the present invention can contain one or several asymmetric carbon atoms.
  • the invention includes the individual diastereomers or enantiomers, and the mixtures thereof.
  • the individual diastereomers or enantiomers may be prepared or isolated by methods already well-known in the art.
  • the method for the formation of the 3-alkyl-4-aminobutanoic acids starting from 2-alkenoic esters is prepared from commercially available aldehydes and monoethyl malonate by the Knoevenagel reaction (Kim Y. C., Cocolase G. H., J. Med. Chem., 1965:8509), with the exception of ethyl 4,4-dimethyl-2-pentenoate.
  • This compound was prepared from 2,2-dimethylpropanal and ethyl lithioacetate, followed by dehydration of the ⁇ -hydroxyester with phosphoryl chloride and pyridine.
  • the compounds made by the synthetic methods can be used as pharmaceutical compositions as agent in the treatment of pain when an effective amount of a compound of the Formula I, together with a pharmaceutically acceptable carrier is used.
  • the pharmaceutical can be used in a method for treating such disorders in mammals, including human, suffering therefrom by administering to such mammals an effective amount of the compound as described above in unit dosage form.
  • the pharmaceutical compound made in accordance with the present invention, can be prepared and administered in a wide variety of dosage forms by either oral or parenteral routes of administration.
  • these pharmaceutical compositions can be made in inert, pharmaceutically acceptable carriers which are either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • Other solid and liquid form preparations could be made in accordance with known methods of the art and administered by the oral route in an appropriate formulation, or by a parenteral route such as intravenous, intramuscular, or subcutaneous injection as a liquid formulation.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to about 300 mg/kg daily, based on an average 70-kg patient. A daily dose range of about 1 mg to about 50 mg/kg is preferred.
  • the dosages may be varied depending upon the requirement with a patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for particular situations is within the skill of the art.
  • mice Male Sprague-Dawley rats (70-90 g) were habituated to perspex observation chambers (24 cm ⁇ 24 cm ⁇ 24 cm) for at least 15 minutes prior to testing.
  • Formalin-induced hind paw licking and biting was initiated by a 50 ⁇ L subcutaneous injection of a 5% formalin solution (5% formaldehyde in isotonic saline) into the plantar surface of the left hind paw.
  • licking/biting of the injected hind paw was scored in 5 minute bins for 60 minutes. The results are expressed as mean combined licking/biting time for the early phase (0-10 minutes) and late phase (10-45 minutes).
  • Nociceptive pressure thresholds were measured in the rat paw pressure test using an analgesimeter (Ugo Basile). A cut-off point of 250 g was used to prevent any damage to the paw. The intraplantar injection of carrageenin produced a reduction in the nociceptive pressure threshold between 3 and 5 hours after injection, indicating induction of hyperalgesia. Morphine (3 mg/kg, s.c.) produced a complete blockade of hyperalgesia (FIG. 2 ). Gabapentin (3-300 mg/kg, s.c.) and CI-1008 (1-100 mg/kg, s.c.) dose-dependently antagonized the hyperalgesia, with respective MED of 10 and 3 mg/kg (FIG. 2 ).
  • Baseline paw withdrawal latencies were obtained for each rat using the Hargreaves model.
  • Carrageenin was injected as described above. Animals were then tested for thermal hyperalgesia at 2 hours postcarrageenin administration. Gabapentin (10-100 mg/kg) or CI-1008 (1-30 mg/kg) was administered s.c. 2.5 hours after carrageenin, and PWL were reevaluated at 3 and 4 hours postcarrageenin administration.
  • Carrageenin induced a significant reduction in paw withdrawal latency at 2, 3, and 4 hours following injection, indicating the induction of thermal hyperalgesia (FIG. 3 ).
  • Gabapentin and CI-1008 dose-dependently antagonized the hyperalgesia with a MED of 30 and 3 mg/kg (FIG. 3 ).
  • the assay of Bennett G. J. provides an animal model of a peripheral mononeuropathy in rat that produces disorder of pain sensation like those seen in man (Pain, 1988;33:87-107).
  • the assay of Kim S. H., et al. provides one experimental model for peripheral neuropathy produced by segmented spinal nerve ligation in the rat (Pain, 1990;50:355-363).
  • mice Male Sprague-Dawley rats (250-300 g), obtained from Bantin and Kingmen, (Hull, U. K.) were used in all experiments. Before surgery, animals were housed in groups of 6 under a 12-hour light/dark cycle (lights on at 07 hour 00 minute) with food and water ad libitum. Postoperatively, animals were housed in pairs on “Aqua-sorb” bedding consisting of air laid cellulose (Beta Medical and Scientific, Sale, U.K.) under the same conditions. All experiments were carried out by an observer blind to drug treatments.
  • Animals were anaesthetized with 2% isofluorane and 1.4 O 2 /NO 2 mixture which was maintained during surgery via a nose cone.
  • the plantar surface of the right hind paw was prepared with 50% ethanol, and a 1-cm longitudinal incision was made through skin and fascia, starting 0.5 cm from the edge of the heel and extending towards the toes.
  • the plantaris muscle was elevated using forceps and incised longitudinally.
  • the wound was closed using two simple sutures of braided silk with a FST-02 needle.
  • the wound site was covered with Terramycin spray and Auromycin powder. Postoperatively, none of the animals displayed any signs of infection with the wounds healing well after 24 hours. The sutures were removed after 48 hours.
  • Tactile allodynia was measured using Semmes-Weinstein von Frey hairs (Stoelting, Ill., U.S.A.). Animals were placed into wire-mesh-bottom cages allowing access to the underside of their paws. The animals were habituated to this environment prior to the start of the experiment. Tactile allodynia was tested by touching the plantar surface of the animals hind paw with von Frey hairs in ascending order of force (0.7, 1.2, 1.5, 2, 3.6, 5.5, 8.5, 11.8, 15. 1, and 29 g) until a paw withdrawal response was elicited. Each von Frey hair was applied to the paw for 6 seconds, or until a response occurred.
  • the allodynia and hyperalgesia peaked within 1 hour in all animals and was maintained for the following 5 to 6 hours.
  • Gabapentin and S-(+)-3-isobutylgaba did not affect PWL in the thermal hyperalgesia test or tactile allodynia scores in the contralateral paw up to the highest dose tested in any of the experiments.
  • morphine (6 mg, s.c.) increased PWL of the contralateral paw in the thermal hyperalgesia test (data not shown).
  • results presented here show that incision of the rat plantaris muscle induces thermal hyperalgesia and tactile allodynia lasting at least 3 days.
  • the major findings of the present study are that gabapentin and S-(+)-3-isobutylgaba are equally effective at blocking both nociceptive responses.
  • morphine was found to be more effective against thermal hyperalgesia than tactile allodynia.
  • S-(+)-3-isobutylgaba completely blocked induction and maintenance of allodynia and hyperalgesia.

Abstract

The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.

Description

Notice: more than one reissue application has been filed for the reissue of U.S. Pat. No. 6,001,876. The reissue applications: are U.S. application Ser. No. 12/700,968 (filed Feb. 5, 2010 ), which is a continuation of the present application; and, the present application.
This application claims benefit of Provisional application Ser. No. 60/022,337, Jul. 24, 1996.
BACKGROUND OF THE INVENTION
The present invention is the use of analogs of glutamic acid and gamma-aminobutyric acid (GABA) in pain therapy, as the compounds exhibit analgesic/antihyperalgesic action. Advantages of the use of the compounds includes the finding that repeated use does not lead to tolerance nor is there a cross-tolerance between morphine and the compounds.
The compounds of the invention are known agents useful in antiseizure therapy for central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischemia, Parkinson's disease, tardive dyskinesia, and spasticity. It has also been suggested that the compounds can be used as antidepressants, anxiolytics, and antipsychotics. See WO 92/09560 (U.S. Ser. No. 618,692 filed Nov. 27, 1990) and WP 93/23383 (U.S. Ser. No. 886,080 filed May 20, 1992).
SUMMARY OF THE INVENTION
The instant invention is a method of using a compound of Formula I below in the treatment of pain, especially for treatment of chronic pain disorders. Such disorders include, but are not limited to, inflammatory pain, postoperative pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, bum burn pain, and other forms of neuralgic, neuropathic, and idiopathic pain syndromes.
A compound are those of Formula I
Figure USRE041920-20101109-C00001
or a pharmaceutically acceptable salt thereof wherein
    • R1 is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;
    • R2 is hydrogen or methyl; and
    • R3 is hydrogen, methyl, or carboxyl.
Diastereomers and enantiomers of compounds of Formula I are included in the invention.
Preferred compounds of the invention are those according to claim 1 wherein R3 and R2 are hydrogen, and R1 is —(CH2)0-2—i C4H9 as an (R), (S), or (R,S) isomer.
The more preferred compounds of the invention are (S)-3-(aminomethyl)-5-methylhexanoic acid and 3-aminomethyl-5-methyl-hexanoic acid.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Effect of Gabapentin (1-(aminomethyl)-cyclohexaneacetic acid), CI-1008 ((S)-3-(aminomethyl)-5-methylhexanoic acid), and 3-aminomethyl-5-methylhexanoic acid in the Rat Paw Formalin Test
Test compounds were administered s.c. 1 hour before an intraplantar injection of 50 μL formalin. The time spent licking/biting the injected paw during the early and late phases was scored. Results are shown as the mean ±SEM of 6 to 8 animals per group. *P<0.05 and **P<0.01 significantly different from vehicle (Veh.) treated controls (ANOVA followed by Dunnett's t-test).
FIG. 2. Effect of Gabapentin and CI-1008 on Carrageenin-Induced Mechanical Hyperalgesia
Nociceptive pressure thresholds were measured in the rat using the paw pressure test. Baseline (BL) measurements were taken before animals were administered with 100 μL of 2% carrageenin by intraplantar injection. Results are shown as mean (±SEM) of 8 animals per group. Gabapentin (GP), CI-1008, or morphine (MOR; 3 mg/g) was administered s.c. 3.5 hours after carrageenin. *P<0.05 and **P<0.01 significantly different from vehicle control group at the same time point (ANOVA followed by Dunnett's t-test).
FIG. 3. Effect of Gabapentin and CI-1008 on Carrageenin-Induced Thermal Hyperalgesia
Nociceptive thermal thresholds were measured in the rat using the Hargreaves apparatus. Baseline (BL) measurements were taken before animal s were administered with 100 μL of 2% carrageenin by intraplantar injection. Results are shown as mean (±SEM) of 8 animals per group. Gabapentin (GP) or CI-1008 was administered s.c. 2.5 hours after carrageenin. *P<0.05 and **P<0.01 significantly different from vehicle control group at the same time point (ANOVA followed by Dunnett's t-test).
FIG. 4. Effect of (a) Morphine, (b) Gabapentin, and (c) S-(+)-3-Isobutylgaba on Thermal Hyperalgesia in the Rat Postoperative Pain Model
Gabapentin or S-(+)-3 isobutylgaba was administered 1 hour before surgery. Morphine was administered 0.5 hour before surgery. Thermal paw withdrawal latencies (PWL) were determined for both ipsilateral and contralateral paws using the rat plantar test. For clarity contralateral paw data for drug-treated animals is not shown. Baseline (BL) measurements were taken before surgery and PWL were reassessed 2, 24, 48, and 72 hours postsurgery. Results are expressed as the mean PWL(s) of 8 to 10 animals per group (vertical bars represent ±SEM). *P<0.05 **P<0.01 significantly different (ANOVA followed by Dunnett's t-test), comparing ipsilateral paw of drug-treated groups to ispsilateral paw of vehicle-treated group at each time point. In the figure, —●— is vehicle contralateral, —◯— is vehicle ispsilateral, —Δ— is 1 mg/kg morphine, —▭— is 3, and —⋄— is 6 for morphine in 4a. In 4b, —Δ— is 3, —▭— is 10, and —⋄— is 30 for gabapentin. In 4c, —Δ— is 3 mg/kg, —▭— is 10, and —⋄— is 30 for S-(+)-isobutylgaba.
FIG. 5 Effect of (a) Morphine, (b) Gabapentin, and (c) S-(+)-3-Isobutylgaba on Tactile Allodynia in the Rat Post-operative Pain Model
Gabapentin or S-(+)-3-isobutylgaba was administered 1 hour before surgery. Morphine was administered 0.5 hour before surgery. Paw withdrawal thresholds to von Frey hair filaments were determined for both ipsilateral and contralateral paws. For clarity, contralateral paw data for drug-treated animals is not shown. Baseline (BL) measurements were taken before surgery, and withdrawal thresholds were reassessed 3, 25, 49, and 73 hours postsurgery. Results are expressed as median force (g) required to induce a withdrawal of paw in 8 to 10 animals per group (vertical bars represent first and third quartiles). *P<0.05 significantly different (Mann Whitney t-test) comparing ipsilateral paw of drug-treated groups to ipsilateral paw of vehicle treated group at each time point. In FIG. 5, —●— is vehicle contralateral, —◯— is vehicle ispsilateral. For morphine (5a), —Δ— is 1 mg/kg, —▭— is 3, and —⋄— is 16.
In 5b for gabapentin and S-(+)-isobutylgaba, —Δ— is 3 mg/kg, —▭— is 10, and —⋄— is 30.
FIG. 6. Effect of S-(+)-3-Isobulylgaba on the Maintenance of (a) Thermal Hyperalgesia and (b) Tactile Allodynia in the Rat Postoperative Pain Model.
S-(+)-3-Isobutylgaba (S-(+)-IBG) was administered 1 hour after surgery. Thermal paw withdrawal latencies, determined using the rat plantar test, and paw withdrawal thresholds to von Frey hair filaments, were determined in separate groups of animals for both ipsilateral and contralateral paws. For clarity only the ipsilateral paw data is shown. Baseline (BL) measurements were taken before surgery and withdrawal thresholds were reassessed up to 6 hours postsurgery. For thermal hyperalgesia, the results are expressed as the mean PWL(s) of 6 animals per group (vertical bars represent ±SEM), *P<0.05 **P<0.01 significantly different (unpaired t-test), comparing ipsilateral paw of drug-treated group to ipsilateral paw of vehicle (Veh —◯—) treated group at each time point. For tactile allodynia, the results are expressed as median force (g) required to induce a paw withdrawal of 6 animals per group (vertical bars represent first and third quartiles). *P<0.05 significantly different (Mann Whitney t-test), comparing ipsilateral paw of drug-treated group to ipsilateral paw of vehicle-treated group at each time point. —●— is S-(+)-IBG at 30 mg/kg.
 DETAILED DESCRIPTION
The instant invention is a method of using a compound of Formula I above as an analgesic in the treatment of pain as listed above. Pain such as inflammatory pain, neuropathic pain, cancer pain, postoperative pain, and idiopathic pain which is pain of unknown origin, for example, phantom limb pain are included especially. Neuropathic pain is caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from.
The conditions listed above are known to be poorly treated by currently marketed analgesics such as narcotics or nonsteroidal anti-inflammatory drugs (NSAID) due to insufficient efficacy or limiting side effects.
The terms used in Formula I are, for example, alkyl which term is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, isopentyl, and neopentyl, as well as those as would occur to one skilled in the art.
The term “cycloalkyl” is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
The compounds of the present invention may form pharmaceutically acceptable salts with both organic and inorganic acids or bases. For example, the acid addition salts of the basic compounds are prepared either by dissolving the free base in aqueous or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution. Examples of pharmaceutically acceptable salts are hydrochlorides, hydrobromides, hydrosulfates, etc. as well as sodium, potassium, and magnesium, etc. salts.
The compounds of the present invention can contain one or several asymmetric carbon atoms. The invention includes the individual diastereomers or enantiomers, and the mixtures thereof. The individual diastereomers or enantiomers may be prepared or isolated by methods already well-known in the art.
The method for the formation of the 3-alkyl-4-aminobutanoic acids starting from 2-alkenoic esters is prepared from commercially available aldehydes and monoethyl malonate by the Knoevenagel reaction (Kim Y. C., Cocolase G. H., J. Med. Chem., 1965:8509), with the exception of ethyl 4,4-dimethyl-2-pentenoate. This compound was prepared from 2,2-dimethylpropanal and ethyl lithioacetate, followed by dehydration of the β-hydroxyester with phosphoryl chloride and pyridine. The Michael addition of nitromethane to α,β-unsaturated compounds mediated by 1,1,3,3-tetramethylguanidine or 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) afforded 4-nitroesters in good yields.
Although the aliphatic nitro compounds are usually reduced by either high pressure catalytic hydrogenation by metal-catalyzed transfer hydrogenation, or by newly introduced hydrogenolysis methods with ammonium formate or sodium borohydride and palladium as catalysts, applicants have found that 4-nitrocarboxylic esters can be reduced almost quantitatively to the corresponding 4-aminocarboxylic esters by hydrogenation using 10% palladium on carbon as catalysts in acetic acid at room temperature and atmospheric pressure. The amino esters produced were subjected to acid hydrolysis to afford the subject inventive compounds in good yields. This procedure provides access to a variety of 3-alkyl-4-aminobutanoic acids as listed in Tables 1 and 2 as examples, and thus is advantageous in comparison to methods previously used.
When the starting material is not commercially available, the synthetic sequence was initiated with the corresponding alcohol, which was oxidized to the aldehyde by the method of Corey, et al., Tetrahedrom. Lett., 1975:2647-2650.
The compounds made by the synthetic methods can be used as pharmaceutical compositions as agent in the treatment of pain when an effective amount of a compound of the Formula I, together with a pharmaceutically acceptable carrier is used. The pharmaceutical can be used in a method for treating such disorders in mammals, including human, suffering therefrom by administering to such mammals an effective amount of the compound as described above in unit dosage form.
The pharmaceutical compound, made in accordance with the present invention, can be prepared and administered in a wide variety of dosage forms by either oral or parenteral routes of administration. For example, these pharmaceutical compositions can be made in inert, pharmaceutically acceptable carriers which are either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. Other solid and liquid form preparations could be made in accordance with known methods of the art and administered by the oral route in an appropriate formulation, or by a parenteral route such as intravenous, intramuscular, or subcutaneous injection as a liquid formulation.
The quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to about 300 mg/kg daily, based on an average 70-kg patient. A daily dose range of about 1 mg to about 50 mg/kg is preferred. The dosages, however, may be varied depending upon the requirement with a patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for particular situations is within the skill of the art.
Effects of Gabapentin, CI-1008, and 3-Aminomethyl-5-methyl-hexanoic Acid in the Rat Formalin Paw Test
Male Sprague-Dawley rats (70-90 g) were habituated to perspex observation chambers (24 cm×24 cm×24 cm) for at least 15 minutes prior to testing. Formalin-induced hind paw licking and biting was initiated by a 50 μL subcutaneous injection of a 5% formalin solution (5% formaldehyde in isotonic saline) into the plantar surface of the left hind paw. Immediately following the formalin injection, licking/biting of the injected hind paw was scored in 5 minute bins for 60 minutes. The results are expressed as mean combined licking/biting time for the early phase (0-10 minutes) and late phase (10-45 minutes).
The s.c. administration of gabapentin (10-300 mg/kg) or CI-1008 (1-100 mg/kg) 1 hour before formalin dose-dependently blocked the licking/biting behavior during the late phase of the formalin response with respective minimum effective doses (MED) of 30 and 10 mg/kg (FIG. 1). However, neither of the compounds affected the early phase at any of the doses tested. Similar administration of 3-aminomethyl-5-methyl-hexanoic acid produced only a modest blockade of the late phase at 100 mg/kg.
Effects of Gabapentin and CI-1008 on Carrageenin-Induced Hyperalgesia
On the test Day, 2 to 3 baseline measurements were taken before rats (male Sprague-Dawley 70-90 g) were administered with 100 μL of 2% carrageenin by intraplantar injection into the right hind paw. Animals were dosed with the test drug after development of peak hyperalgesia. Separate groups of animals were used for the mechanical and thermal hyperalgesia studies.
A. Mechanical Hyperalgesia
Nociceptive pressure thresholds were measured in the rat paw pressure test using an analgesimeter (Ugo Basile). A cut-off point of 250 g was used to prevent any damage to the paw. The intraplantar injection of carrageenin produced a reduction in the nociceptive pressure threshold between 3 and 5 hours after injection, indicating induction of hyperalgesia. Morphine (3 mg/kg, s.c.) produced a complete blockade of hyperalgesia (FIG. 2). Gabapentin (3-300 mg/kg, s.c.) and CI-1008 (1-100 mg/kg, s.c.) dose-dependently antagonized the hyperalgesia, with respective MED of 10 and 3 mg/kg (FIG. 2).
B. Thermal Hyperalgesia
Baseline paw withdrawal latencies (PWL) were obtained for each rat using the Hargreaves model. Carrageenin was injected as described above. Animals were then tested for thermal hyperalgesia at 2 hours postcarrageenin administration. Gabapentin (10-100 mg/kg) or CI-1008 (1-30 mg/kg) was administered s.c. 2.5 hours after carrageenin, and PWL were reevaluated at 3 and 4 hours postcarrageenin administration. Carrageenin induced a significant reduction in paw withdrawal latency at 2, 3, and 4 hours following injection, indicating the induction of thermal hyperalgesia (FIG. 3). Gabapentin and CI-1008 dose-dependently antagonized the hyperalgesia with a MED of 30 and 3 mg/kg (FIG. 3).
These data show that gabapentin and CI-1008 are effective in the treatment of inflammatory pain.
The assay of Bennett G. J. provides an animal model of a peripheral mononeuropathy in rat that produces disorder of pain sensation like those seen in man (Pain, 1988;33:87-107).
The assay of Kim S. H., et al., provides one experimental model for peripheral neuropathy produced by segmented spinal nerve ligation in the rat (Pain, 1990;50:355-363).
A rat model of postoperative pain has been described (Brennan et al., 1996). It involves an incision of the skin, fascia, and muscle of the plantar aspect of the hind paw. This leads to an induction of reproducible and quantifiable mechanical hyperalgesia lasting several days. It has been suggested that this model displays some similarities to the human postoperative pain state. In the present study we have examined and compared the activities of gabapentin and S-(+)-3-isobutylgaba with morphine in this model of post-operative pain.
METHODS
Male Sprague-Dawley rats (250-300 g), obtained from Bantin and Kingmen, (Hull, U. K.) were used in all experiments. Before surgery, animals were housed in groups of 6 under a 12-hour light/dark cycle (lights on at 07 hour 00 minute) with food and water ad libitum. Postoperatively, animals were housed in pairs on “Aqua-sorb” bedding consisting of air laid cellulose (Beta Medical and Scientific, Sale, U.K.) under the same conditions. All experiments were carried out by an observer blind to drug treatments.
Surgery
Animals were anaesthetized with 2% isofluorane and 1.4 O2/NO2 mixture which was maintained during surgery via a nose cone. The plantar surface of the right hind paw was prepared with 50% ethanol, and a 1-cm longitudinal incision was made through skin and fascia, starting 0.5 cm from the edge of the heel and extending towards the toes. The plantaris muscle was elevated using forceps and incised longitudinally. The wound was closed using two simple sutures of braided silk with a FST-02 needle. The wound site was covered with Terramycin spray and Auromycin powder. Postoperatively, none of the animals displayed any signs of infection with the wounds healing well after 24 hours. The sutures were removed after 48 hours.
Evaluation of Thermal Hyperalgesia
Thermal hyperalgesia was assessed using the rat plantar test (Ugo Basile, Italy) following a modified method of Hargreaves, et al., 1988. Rats were habituated to the apparatus which consisted of three individual perspex boxes on an elevated glass table. A mobile radiant heat source was located under the table and focused onto the hind paw and paw withdrawal latencies (PWL) were recorded. There was an automatic cut off point of 22.5 seconds to prevent tissue damage. PWLs were taken 2 to 3 times for both hind paws of each animal, the mean of which represented baselines for right and left hind paws. The apparatus was calibrated to give a PWL of approximately 10 seconds. PWL(s) were reassessed following the same protocol as above 2, 24, 48, and 72 hours postoperatively.
Evaluation of Tactile Allodynia
Tactile allodynia was measured using Semmes-Weinstein von Frey hairs (Stoelting, Ill., U.S.A.). Animals were placed into wire-mesh-bottom cages allowing access to the underside of their paws. The animals were habituated to this environment prior to the start of the experiment. Tactile allodynia was tested by touching the plantar surface of the animals hind paw with von Frey hairs in ascending order of force (0.7, 1.2, 1.5, 2, 3.6, 5.5, 8.5, 11.8, 15. 1, and 29 g) until a paw withdrawal response was elicited. Each von Frey hair was applied to the paw for 6 seconds, or until a response occurred. Once a withdrawal response was established, the paw was retested, starting with the next descending von Frey hair until no response occurred. The highest force of 29 g lifted the paw as well as eliciting a response, thus represented the cut-off point. Each animal had both hind paws tested in this manner. The lowest amount of force required to elicit a response was recorded as withdrawal threshold in grams. When compounds were administered before surgery, the same animals were used to study drug effects on tactile, allodynia, and thermal hyperalgasia, with each animal being tested for tactile allodynia 1 hour after thermal hyperalgesia. Separate groups of animals were used for examination of tactile allodynia and thermal hyperalgesia when S-(+)-3-isobutylgaba was administered after surgery.
Statistics
Data obtained for thermal hyperalgesia was subjected to a one-way (analysis of variance) ANOVA followed by a Dunnett's t-test. Tactile allodynia results obtained with the von Frey hairs were subjected to an individual Mann Whitney t-test.
RESULTS
An incision of the rat plantaris muscle led to an induction of thermal hyperalgesia and tactile allodynia. Both nociceptive responses peaked within 1 hour following surgery and were maintained for 3 days. During the experimental period, all animals remained in good health.
Effect of Gabapentin. S-(+)-3-Isobutylgaba and Morphine Administered Before Surgery on Thermal Hyperalgesia
The single-dose administration of gabapentin 1 hour before surgery dose-dependently (3-30 mg/kg, s.c.) blocked development of thermal hyperalgesia with a MED of 30 mg/kg (FIG. 1b). The highest dose of 30 mg/kg gabapentin prevented the hyperalgesic response for 24 hours (FIG. 1b). Similar administration of S-(+)-3-isobutylgaba also dose-dependently (3-30 mg/kg, s.c.) prevented development of thermal hyperalgesia with a MED of 3 mg/kg (FIG. 1c). The 30 mg/kg dose of S-(+)-3-isobutylgaba was effective up to 3 days (FIG. 1c). The administration of morphine 0.5 hour before surgery dose-dependently (1-6 mg/kg, s.c.) antagonized the development of thermal hyperalgesia with a MED of 1 mg/kg (FIG. 1a). This effect was maintained for 24 hours (FIG. 1a).
Effects of Gabapentin, S-(+)-3-Isobutylgaba and Morphine Administered Before Surgery on Tactile Allodynia
The effect of drugs on development of tactile allodynia was determined in the same animals used for thermal hyperalgesia above. One hour was allowed between thermal hyperalgesia and tactile allodynia tests. Gabapentin dose-dependently prevented development of tactile allodynia with a MED of 10 mg/kg. The 10 and 30 mg/kg doses of gabapentin were effective for 25 and 49 hours, respectively (FIG. 2b). S-(+)-3-Isobutylgaba also dose-dependently (3-30 mg/kg) blocked development of the allodynia response with a MED of 10 mg/kg (FIG. 2c). This blockade of the nociceptive response was maintained for 3 days by the 30 mg/kg dose of S-(+)-3-isobutylgaba (FIG. 2c). In contrast, morphine (1-6 mg/kg) only prevented the development of tactile allodynia for 3 hour postsurgery at the highest dose of 6 mg/kg (FIG. 2a).
Effect of S-(+)-3-Isobutylgaba Administered 1 Hour After Surgery on Tactile Allodynia and Thermal Hyperalgesia
The allodynia and hyperalgesia peaked within 1 hour in all animals and was maintained for the following 5 to 6 hours. The s.c. administration of 30 mg/kg S-(+)-3-isobutylgaba 1 hour after surgery blocked the maintenance of tactile allodynia and thermal hyperalgesia for 3 to 4 hours. After this time, both nociceptive responses returned to control levels indicating disappearance of antihyperalgesic and antiallodynic actions (FIG. 3).
Gabapentin and S-(+)-3-isobutylgaba did not affect PWL in the thermal hyperalgesia test or tactile allodynia scores in the contralateral paw up to the highest dose tested in any of the experiments. In contrast, morphine (6 mg, s.c.) increased PWL of the contralateral paw in the thermal hyperalgesia test (data not shown).
The results presented here show that incision of the rat plantaris muscle induces thermal hyperalgesia and tactile allodynia lasting at least 3 days. The major findings of the present study are that gabapentin and S-(+)-3-isobutylgaba are equally effective at blocking both nociceptive responses. In contrast, morphine was found to be more effective against thermal hyperalgesia than tactile allodynia. Furthermore, S-(+)-3-isobutylgaba completely blocked induction and maintenance of allodynia and hyperalgesia.

Claims (25)

1. A method for treating pain comprising administering a therapeutically effective amount of a compound of Formula I
Figure USRE041920-20101109-C00002
or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof wherein
R1 is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;
R2 is hydrogen or methyl; and
R3 is hydrogen, methyl, or carboxyl to a mammal in need of said treatment.
2. A method according to claim 1 for treating pain comprising administering a therapeutically effective amount of a compound of Formula I
Figure USRE041920-20101109-C00003
or a pharmaceutically acceptable salt thereof, wherein the compound administered is a compound of Formula I wherein R 3 and R2 are hydrogen, and R1 is —(CH2)0-2—i C4H9isobutyl as an (R), (S), or (R,S) isomer, to a mammal in need of said treatment.
3. A method according to claim 1 wherein the compound administered is named (S)-3-(aminomethyl)-5-methylhexanoic acid and 3-aminomethyl-5-methylhexanoic acid.
4. A method according to claim 1 2 wherein the pain treated is inflammatory pain.
5. A method according to claim 1 2 wherein the pain treated is neuropathic pain.
6. A method according to claim 1 2 wherein the pain treated is cancer pain.
7. A method according to claim 1 2 wherein the pain treated is postoperative pain.
8. A method according to claim 1 2 wherein the pain treated is phantom limit limb pain.
9. A method according to claim 1 2 wherein the pain treated is bum burn pain.
10. A method according to claim 1 2 wherein the pain treated is gout pain.
11. A method according to claim 1 2 wherein the pain treated is osteoarthritic pain.
12. A method according to claim 1 2 wherein the pain treated is trigeminal neuralgia pain.
13. A method according to claim 1 2 wherein the pain treated is acute herpetic and postherpetic pain.
14. A method according to claim 1 2 wherein the pain treated is causalgia pain.
15. A method according to claim 1 2 wherein the pain treated is idiopathic pain.
16. A method for treating pain comprising administering a therapeutically effective amount of (S)- 3 -(aminomethyl)- 5 -methylhexanoic acid, or a pharmaceutically acceptable salt thereof, to a human in need of said treatment.
17. A method according to claim 16 wherein the compound administered is (S)- 3 -(aminomethyl)- 5 -methylhexanoic acid.
18. A method according to claim 16 wherein the compound administered is a pharmaceutically acceptable salt of (S)- 3 -(aminomethyl)- 5 -methylhexanoic acid.
19. A method according to claim 17 wherein the pain treated is chronic pain.
20. A method according to claim 17 wherein the pain treated is selected from the group consisting of inflammatory pain, neuropathic pain, cancer pain, postoperative pain, and idiopathic pain.
21. A method according to claim 17 wherein the pain treated is neuropathic pain.
22. A method according to claim 17 wherein the pain treated is diabetic neuropathic pain.
23. A method according to claim 17 wherein the pain treated is acute herpetic pain.
24. A method according to claim 17 wherein the pain treated is postherpetic pain.
25. A method according to claim 17 wherein the pain treated is fibromyalgia pain.
US11/983,750 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain Expired - Lifetime USRE41920E1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2233796P 1996-07-24 1996-07-24
PCT/US1997/012390 WO1998003167A1 (en) 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/043,358 Reissue US6001876A (en) 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
USRE41920E1 true USRE41920E1 (en) 2010-11-09

Family

ID=21809080

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/043,358 Expired - Lifetime US6001876A (en) 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain
US11/983,750 Expired - Lifetime USRE41920E1 (en) 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/043,358 Expired - Lifetime US6001876A (en) 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain

Country Status (24)

Country Link
US (2) US6001876A (en)
EP (1) EP0934061B3 (en)
JP (1) JP3693258B2 (en)
KR (1) KR100491282B1 (en)
CN (1) CN1094757C (en)
AT (1) ATE241351T1 (en)
AU (1) AU714980B2 (en)
BR (1) BR9710536A (en)
CA (1) CA2255652C (en)
CU (1) CU22850A3 (en)
DE (1) DE69722426T3 (en)
DK (1) DK0934061T6 (en)
ES (1) ES2200184T7 (en)
HK (1) HK1021134A1 (en)
HR (1) HRP970387A2 (en)
HU (2) HU228426B1 (en)
IL (1) IL126999A (en)
NO (2) NO325822B1 (en)
NZ (1) NZ332762A (en)
PL (1) PL189872B1 (en)
PT (1) PT934061E (en)
SI (1) SI0934061T1 (en)
WO (1) WO1998003167A1 (en)
ZA (1) ZA976562B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018143512A1 (en) 2017-02-01 2018-08-09 지엘팜텍 주식회사 High-swelling sustained-release triple tablet containing pregabalin
WO2018143511A1 (en) 2017-02-01 2018-08-09 지엘팜텍 주식회사 Oral sustained-release triple tablet containing pregabalin

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
BR9812162A (en) * 1997-09-08 2000-07-18 Warner Lambert Co Analgesic compositions comprising antiepileptic compounds and methods for using them
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
DK1077692T3 (en) * 1998-05-15 2004-12-06 Warner Lambert Co Amino acid stabilized gabapentin and pregabalin preparations and methods for their preparation
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
ATE305778T1 (en) * 1998-07-09 2005-10-15 Warner Lambert Co TREATMENT OF RENAL COLIC WITH GABA ANALOGUES
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
CA2332927A1 (en) * 1998-07-09 2000-01-20 Catherine A. Segal Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain
EP1093366B1 (en) * 1998-07-09 2004-10-13 Warner-Lambert Company LLC Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
ATE419231T1 (en) * 1999-06-10 2009-01-15 Warner Lambert Co MONO-SUBSTITUTED 3-PROPYL-GAMMA-AMINOBUTTERIC ACID
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical compositions for treatment of neuropathy comprising an inhibitor of cyclic guanosine 3',5'-monophosphate phosphodiesterase 5 and either gabapentin or pregabalin
PT1250311E (en) * 2000-01-27 2004-07-30 Warner Lambert Co PREGABALINE ASYMMETRIC SYNTHESIS
US6687187B2 (en) * 2000-08-11 2004-02-03 Phonak Ag Method for directional location and locating system
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
DE60120104T2 (en) * 2001-03-20 2006-09-21 Schwarz Pharma Ag New use of peptide compounds in the treatment of non-neuropathic inflammatory pain
DK1243263T3 (en) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hitherto unknown use of a class of peptide compounds to treat allodynia or other various types of chronic or phantom pain
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) * 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
EP1412324A4 (en) * 2001-06-11 2004-09-29 Xenoport Inc Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP4350508B2 (en) 2001-09-03 2009-10-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー Pharmaceutical composition containing gabapentin or an analog thereof and α-aminoamide and analgesic use thereof
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
PL377520A1 (en) * 2002-12-13 2006-02-06 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
WO2004054564A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
KR100845932B1 (en) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders
KR20090118994A (en) 2002-12-13 2009-11-18 워너-램버트 캄파니 엘엘씨 Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
KR100828218B1 (en) 2003-09-12 2008-05-07 화이자 인코포레이티드 Combinations comprising alpha-2-delta ligands and serotonin/noradrenaline re-uptake inhibitors
MXPA06003043A (en) * 2003-09-17 2006-05-31 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs.
SI1677767T1 (en) 2003-10-14 2011-11-30 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
WO2005053667A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1727620B1 (en) * 2004-03-12 2007-08-29 Warner-Lambert Company LLC C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
WO2005095424A1 (en) * 2004-04-01 2005-10-13 Warner-Lambert Company Llc Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
KR20070007931A (en) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
DE602005018965D1 (en) * 2004-06-21 2010-03-04 Warner Lambert Co PREPARATION OF PREGABALIN AND RELATED COMPOUNDS
DE602005021970D1 (en) * 2004-08-27 2010-08-05 Ucb Pharma Gmbh USE OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN BY BONE CANCER, CHEMOTHERAPY AND NUCLEOSIDE-RELATED PAIN
CN101068538A (en) * 2004-11-04 2007-11-07 什诺波特有限公司 Gaba analog prodrug sustained release oral dosage forms
CA2604602A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
CA2604624A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
DE112006001234T5 (en) * 2005-05-16 2008-04-10 Johnson, Joseph, Knoxville Method and composition for the treatment of ARG
EP1940380A2 (en) * 2005-05-20 2008-07-09 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
KR20080034205A (en) * 2005-09-19 2008-04-18 테바 파마슈티컬 인더스트리즈 리미티드 Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
EP2019817A2 (en) * 2006-05-24 2009-02-04 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
PL2462990T3 (en) 2006-06-15 2014-05-30 Ucb Pharma Gmbh Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect
MX2008014759A (en) * 2007-03-22 2009-03-09 Teva Pharma Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid.
US20090137842A1 (en) * 2007-10-03 2009-05-28 Vollerner Yuri Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010070593A2 (en) 2008-12-19 2010-06-24 Pfizer Ireland Pharmaceuticals Malonate esters
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
WO2010131054A1 (en) * 2009-05-15 2010-11-18 Bradford Pharma Limited Redox drug derivatives
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
HU230031B1 (en) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Stabilized pharmaceutical composition containing pregabalin and isomalt
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
WO2012025861A1 (en) 2010-08-23 2012-03-01 Pfizer Manufacturing Ireland Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
CA2863371A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Pregabalin gr tablets
AU2013213769A1 (en) 2012-01-30 2014-08-21 Sun Pharmaceutical Industries Limited Gastroretentive tablets
CN102966602B (en) * 2012-12-14 2015-08-05 江苏海鸥冷却塔股份有限公司 The energy-conservation water conservancy diversion air duct of a kind of cooling tower
EP2946777B1 (en) 2013-01-18 2023-10-04 Kemphys Ltd. Medicine for treatment of neuropathic disease
HUE034834T2 (en) 2013-03-27 2018-03-28 Pfizer Ireland Pharmaceuticals Process and intermediates for the preparation of pregabalin
MA44212A (en) 2015-05-26 2018-12-26 Isa Odidi Sustained-release pregabalin
GB201617380D0 (en) * 2016-10-13 2016-11-30 St George's Hospital Medical School Treatment for Osteoarthritis
GB201703123D0 (en) * 2017-02-27 2017-04-12 St George's Hospital Medical School Biomarkers
KR20210013081A (en) 2018-05-14 2021-02-03 엑스진 파마슈티컬 인크. Crystalline form of 1-(acyloxy)-alkyl carbamate drug complex of naproxen and pregabalin
CN108926573A (en) * 2018-07-03 2018-12-04 泓博元生命科技（深圳）有限公司 A kind of NADH composition and preparation method and application reducing uric acid index
KR20200056719A (en) 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 Composition Including Gabapentinoids for Neural Regeneration or Neural Restoration in Patient with Spinal Cord Injury
WO2021191108A1 (en) 2020-03-23 2021-09-30 Plus Vitech, S.L. Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid
WO2022038131A1 (en) 2020-08-19 2022-02-24 Plus Vitech, S.L. Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage
WO2022234110A1 (en) 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy
WO2022243430A1 (en) 2021-05-20 2022-11-24 Plus Vitech, S.L. Treatment of acne
WO2022253748A1 (en) 2021-06-03 2022-12-08 Plus Vitech, S.L. Combinations for the treatment of hpv

Citations (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471548A (en) 1963-07-09 1969-10-07 Ciba Geigy Corp Gamma-amino-beta-(para-halophenyl)-butyric acids and their esters
JPS4940460Y2 (en) 1971-05-19 1974-11-06
US4024175A (en) 1974-12-21 1977-05-17 Warner-Lambert Company Cyclic amino acids
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4123438A (en) 1975-03-05 1978-10-31 Stamicarbon, B.V. Process for preparing 2-pyrrolidones
US4322440A (en) 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
EP0024965B1 (en) 1979-07-26 1983-04-27 Merrell Toraude Et Compagnie Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them
US4479005A (en) 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
WO1985000520A1 (en) 1983-08-01 1985-02-14 The Mclean Hospital Corporation Gaba esters and gaba analogue esters
GB2126224B (en) 1982-08-20 1986-05-21 Midit Derivatives of w-amino acids the preparation and utilisation thereof and the compositions containing these derivatives
EP0088593B1 (en) 1982-03-05 1987-05-27 Eli Lilly And Company 1,2,4-triazine and pyrazine derivatives
EP0181833B1 (en) 1984-10-12 1990-05-02 Ciba-Geigy Ag Substituted propane-phosphonous acid compounds
EP0368766A1 (en) 1988-10-28 1990-05-16 Eastman Kodak Company Tabletable formulations and tablets produced therefrom
EP0300448B1 (en) 1987-07-21 1991-04-24 Mitsubishi Kasei Corporation Separation medium
US5023269A (en) 1986-12-22 1991-06-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
EP0419247A3 (en) 1989-09-20 1992-01-08 John Wyeth & Brother Limited Selective gaba antagonists, especially isoquinoline derivatives, and their use for treating cns disorders
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
CA1304080C (en) 1985-06-20 1992-06-23 Isao Hayakawa Optically active pyridobenzoxazine derivatives and intermediates thereof
WO1992014443A1 (en) 1991-02-20 1992-09-03 Warner-Lambert Company Microsphere-in-oil emulsion
EP0353350B1 (en) 1987-01-13 1993-02-17 Daicel Chemical Industries, Ltd. A process for preparing n-substituted amino acid esters
WO1993012811A1 (en) 1991-12-20 1993-07-08 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising growth hormone and asparagine
WO1993023383A1 (en) 1992-05-20 1993-11-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
EP0414263B1 (en) 1989-08-25 1994-10-26 Gödecke Aktiengesellschaft Process for the stabilisation of a solid pharmaceutical composition comprising cyclic amino acids.
WO1994025016A1 (en) 1993-04-23 1994-11-10 Glaxo Group Limited Novel medical use for gaba agonists
EP0399949B1 (en) 1989-05-13 1995-04-12 Ciba-Geigy Ag Substituted aminoalkylphosphinic acids
JPH07215863A (en) 1993-12-21 1995-08-15 Eli Lilly & Co Non-peptidotachykinin receptor antagonist
WO1995032730A1 (en) 1994-05-26 1995-12-07 Novo Nordisk A/S A pharmaceutical preparation comprising glucagon
WO1996003122A2 (en) 1994-07-27 1996-02-08 Warner-Lambert Company Use of gabapentin in the treatment of anxiety and panic
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
WO1996015782A1 (en) 1994-11-18 1996-05-30 The General Hospital Corporation A method for treating vascular headaches
WO1996011680A3 (en) 1994-10-14 1996-06-27 Glaxo Group Ltd Use of gaba agonists in the treatment of emesis
WO1996021661A1 (en) 1995-01-12 1996-07-18 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
WO1996026929A1 (en) 1995-02-28 1996-09-06 H. Lundbeck A/S 4-aminotetrahydrobenzisoxazole or -isothiazole compounds
US5563175A (en) 1990-11-27 1996-10-08 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US5616793A (en) 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
WO1997029101A1 (en) 1996-02-07 1997-08-14 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
WO1997039768A1 (en) 1996-04-24 1997-10-30 Novo Nordisk A/S A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
US5792796A (en) 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
WO1998058641A1 (en) 1997-06-25 1998-12-30 Warner-Lambert Company Use of gaba analogs such as gabapentin in the manufacture of a medicament for treating inflammatory diseases
US5998435A (en) 1996-06-26 1999-12-07 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
US6020370A (en) 1996-03-14 2000-02-01 Warner-Lambert Company Bridged cyclic amino acids as pharmaceutical agents
WO1999059573A9 (en) 1998-05-15 2000-05-04 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6103932A (en) 1996-03-14 2000-08-15 Warner-Lambert Company Substituted cyclic amino acids as pharmaceutical agents
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
WO2000061234A1 (en) 1999-04-09 2000-10-19 Warner-Lambert Company Combinations of gaba analogs and tricyclic compounds to treat depression
WO1999059572A8 (en) 1998-05-15 2000-12-21 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
WO2001001983A1 (en) 1999-07-02 2001-01-11 Warner-Lambert Company A synergistic combination: gabapentin and pregabalin
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
WO2001024791A1 (en) 1999-10-07 2001-04-12 Warner-Lambert Company Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders
US6242488B1 (en) 1997-08-20 2001-06-05 University Of Oklahoma Method for preventing and treating pain
US6306910B1 (en) 1998-07-09 2001-10-23 Warner-Lambert Company Use of Gaba-analogues for treating insomnia
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6326374B1 (en) 1998-07-09 2001-12-04 Warner-Lambert Company Compositions comprising GABA analogs and caffeine
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6359005B1 (en) 1998-10-16 2002-03-19 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
US20020058706A1 (en) 2000-09-22 2002-05-16 Schrier Denis J. Method for treating asthma using pregabalin
US20020072533A1 (en) 2000-10-17 2002-06-13 Denis Schrier Method of treating cartilage damage
US6436974B1 (en) 1999-06-02 2002-08-20 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6521650B1 (en) 1997-12-16 2003-02-18 Pfizer, Inc. Amines as pharmaceutical agents
US20030045449A1 (en) 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US20030045500A1 (en) 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
US6544998B2 (en) 2000-11-30 2003-04-08 Pfizer Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
US6579879B2 (en) 2001-03-30 2003-06-17 Pfizer Inc Pyridazinone aldose reductase inhibitors
US6593368B2 (en) 1997-09-08 2003-07-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6596900B2 (en) 2001-04-19 2003-07-22 Pfizer Inc Fused bicyclic or tricyclic amino acids
US6605745B2 (en) 2000-12-13 2003-08-12 Hoge, Ii Garrett Stewart Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US20040002543A1 (en) 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
US20040006073A1 (en) 2002-06-27 2004-01-08 Dooley David James Method of treating attention deficit hyperactivity disorder
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
US6689915B2 (en) 2001-03-19 2004-02-10 Warner-Lambert Company Llc Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation
US6703522B2 (en) 2000-08-01 2004-03-09 Warner-Lambert Company Alkyl amino acid derivatives useful as pharmaceutical agents
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US6720348B2 (en) 2000-11-30 2004-04-13 Pfizer Inc Combination of gaba agonists and aldose reductase Inhibitors
US6730674B2 (en) 2001-02-28 2004-05-04 Pfizer Inc Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US20040132636A1 (en) 2002-12-13 2004-07-08 Dooley David James Pharmaceutical uses for alpha2delta ligands
US20040138305A1 (en) 2002-12-13 2004-07-15 Taylor Charles Price Alpha2delta ligands for the treatment of fibromyalgia and other disorders
US20050004177A1 (en) 2003-07-02 2005-01-06 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050004106A1 (en) 2003-05-16 2005-01-06 Pfizer Inc Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics
US20050059715A1 (en) 2003-09-12 2005-03-17 Dooley David James Combinations comprising alpha-2-delta ligands
US20050059654A1 (en) 2003-09-12 2005-03-17 Arneric Stephen P. Method for treatment of depression and anxiety disorders by combination therapy
US20050065176A1 (en) 2003-09-22 2005-03-24 Field Mark John Combinations
US6891059B2 (en) 2000-01-27 2005-05-10 Warner-Lambert Company Asymmetric synthesis of pregabalin
US6894047B2 (en) 2001-03-30 2005-05-17 Pfizer Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US20050148573A1 (en) 2003-09-03 2005-07-07 Pfizer Inc. Benzimidazolone compounds having 5-HT4 receptor agonistic activity
US6924377B2 (en) 2002-04-30 2005-08-02 Warner-Lambert Company Process for preparing highly functionalized γ-butyrolactams and γ-amino acids
US20050171203A1 (en) 2003-12-18 2005-08-04 Pfizer Inc. Pregabalin composition
US20050182049A1 (en) 2004-01-29 2005-08-18 Pfizer Inc Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists
US20050222464A1 (en) 2004-04-01 2005-10-06 Hoge Garrett S Ii Preparation of P-chirogenic phospholanes and their use in asymmetric synthesis
US20050228190A1 (en) 2004-03-12 2005-10-13 Jian Bao C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
US20050277672A1 (en) 2004-06-15 2005-12-15 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US20050283023A1 (en) 2004-06-21 2005-12-22 Shanghui Hu Preparation of pregabalin and related compounds
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
WO2006008640A1 (en) 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
US6992109B1 (en) 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
US7026505B2 (en) 2002-01-31 2006-04-11 Warner-Lambert Company Method of treating tinnitus
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
WO2005102390A3 (en) 2004-04-22 2006-05-11 Pfizer Japan Inc Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7067262B2 (en) 2000-05-16 2006-06-27 Warner Lambert Company Llc Cell line for the expression of an α2δ2 calcium channel subunit and methods of use
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7074814B2 (en) 2003-06-05 2006-07-11 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
WO2005102389A3 (en) 2004-04-20 2006-08-17 Pfizer Prod Inc Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
US7138406B2 (en) 2002-07-08 2006-11-21 Pfizer, Inc. Modulators of the glucocorticoid receptor
US7141695B2 (en) 2002-01-25 2006-11-28 Grunenthal Gmbh Methods for producing substituted acrylic acid esters and use of the latter for producing substituted γ-amino acids
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
CA2265615C (en) 1996-09-18 2007-01-30 Astra Aktiebolag Reflux inhibitors
US7205295B2 (en) 2002-12-06 2007-04-17 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as therapeutic agents
WO2006123247A3 (en) 2005-05-20 2007-04-26 Pfizer Ltd Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
US7214824B2 (en) 2004-11-10 2007-05-08 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
US7217721B2 (en) 2002-04-08 2007-05-15 Pfizer, Inc. Tropane derivatives useful in therapy
CA2530904A1 (en) 2005-12-20 2007-06-20 John Marino Pharmaceutical agents for the treatment of pain associated with spinal cord injury
US7235363B2 (en) 1999-09-16 2007-06-26 Warner-Lambert Company Method for the screening of α2δ-1 subunit binding ligands
US7235657B2 (en) 2004-06-29 2007-06-26 Pfizer Inc. Methods for preparing P2X7 inhibitors
US7256216B2 (en) 2001-05-25 2007-08-14 Warner-Lambert Company Llc Liquid pharmaceutical compositions
US20070191350A1 (en) 2004-03-08 2007-08-16 Pifizer Inc. Combinations comprising alpha-2-delta ligands
US20070191462A1 (en) 2004-09-07 2007-08-16 Pfizer Limited Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
US20070196905A1 (en) 2004-04-14 2007-08-23 Pfizer Inc. Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids
WO2007052125A3 (en) 2005-11-02 2007-09-07 Pfizer Prod Inc Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
WO2007102058A1 (en) 2006-03-06 2007-09-13 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
US7279486B2 (en) 2004-03-29 2007-10-09 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7423054B2 (en) 2004-11-29 2008-09-09 Warner Lambert Company Llc Therapeutic pyrazolo[3,4-b]pyridines and indazoles
US7425569B2 (en) 2005-11-08 2008-09-16 Pfizer Inc 1H-pyrazoles useful in therapy
US20080293746A1 (en) 2007-05-01 2008-11-27 Pfizer, Inc. Combinations comprising pregabalin
US7482375B2 (en) 2005-04-20 2009-01-27 Pfizer Inc. Compounds useful in therapy
US7491835B2 (en) 2003-09-25 2009-02-17 Pfizer Inc Prodrugs of amino acids with affinity for the α2δ-protein
US7507742B2 (en) 2005-12-02 2009-03-24 Pfizer Inc. Spirocyclic derivatives
US7514457B2 (en) 2005-05-31 2009-04-07 Pfizer Inc. Substituted aryloxymethyl bicyclicmethyl acetamide compounds
US7547714B2 (en) 2007-02-02 2009-06-16 Pfizer, Inc. Tricyclic compounds, compositions, and methods
US20090170897A1 (en) 2004-04-20 2009-07-02 Pfizer, Inc. Method of Treating Neuropathic Pain
US7566739B2 (en) 2005-03-10 2009-07-28 Pfizer Inc. Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US7572797B2 (en) 2005-11-04 2009-08-11 Pfizer Inc. Amino substituted pyrazine derivatives for the treatment of pain
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US7589109B2 (en) 2005-02-22 2009-09-15 Pfizer Inc Oxyindole derivatives
US7595329B2 (en) 2004-06-15 2009-09-29 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US7598393B2 (en) 2004-11-02 2009-10-06 Pfizer Inc. Sulfonyl benzimidazole derivatives
US7612226B2 (en) 2005-04-28 2009-11-03 Pfizer Inc. Amino acid derivatives
US7622589B2 (en) 2005-03-17 2009-11-24 Pfizer Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
US20090318451A1 (en) 2007-01-15 2009-12-24 Pfizer Inc. Morpholine dopamine agonists for the treatment of pain
US7649004B2 (en) 2004-07-23 2010-01-19 Pfizer, Inc. Pyridine derivatives
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders

Patent Citations (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471548A (en) 1963-07-09 1969-10-07 Ciba Geigy Corp Gamma-amino-beta-(para-halophenyl)-butyric acids and their esters
JPS4940460Y2 (en) 1971-05-19 1974-11-06
US4024175A (en) 1974-12-21 1977-05-17 Warner-Lambert Company Cyclic amino acids
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4123438A (en) 1975-03-05 1978-10-31 Stamicarbon, B.V. Process for preparing 2-pyrrolidones
EP0024965B1 (en) 1979-07-26 1983-04-27 Merrell Toraude Et Compagnie Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them
US4322440A (en) 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
EP0088593B1 (en) 1982-03-05 1987-05-27 Eli Lilly And Company 1,2,4-triazine and pyrazine derivatives
GB2126224B (en) 1982-08-20 1986-05-21 Midit Derivatives of w-amino acids the preparation and utilisation thereof and the compositions containing these derivatives
US4479005A (en) 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
WO1985000520A1 (en) 1983-08-01 1985-02-14 The Mclean Hospital Corporation Gaba esters and gaba analogue esters
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
EP0181833B1 (en) 1984-10-12 1990-05-02 Ciba-Geigy Ag Substituted propane-phosphonous acid compounds
CA1304080C (en) 1985-06-20 1992-06-23 Isao Hayakawa Optically active pyridobenzoxazine derivatives and intermediates thereof
US5023269A (en) 1986-12-22 1991-06-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
EP0353350B1 (en) 1987-01-13 1993-02-17 Daicel Chemical Industries, Ltd. A process for preparing n-substituted amino acid esters
EP0300448B1 (en) 1987-07-21 1991-04-24 Mitsubishi Kasei Corporation Separation medium
EP0368766A1 (en) 1988-10-28 1990-05-16 Eastman Kodak Company Tabletable formulations and tablets produced therefrom
EP0399949B1 (en) 1989-05-13 1995-04-12 Ciba-Geigy Ag Substituted aminoalkylphosphinic acids
US6054482A (en) 1989-08-25 2000-04-25 Godecke Aktiengesellschaft Lactam-free amino acids
EP0414263B1 (en) 1989-08-25 1994-10-26 Gödecke Aktiengesellschaft Process for the stabilisation of a solid pharmaceutical composition comprising cyclic amino acids.
EP0419247A3 (en) 1989-09-20 1992-01-08 John Wyeth & Brother Limited Selective gaba antagonists, especially isoquinoline derivatives, and their use for treating cns disorders
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0446570B1 (en) 1990-01-02 1995-08-02 Warner-Lambert Company Gabapentin and its derivatives for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6414024B1 (en) 1990-11-27 2002-07-02 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6342529B1 (en) 1990-11-27 2002-01-29 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US6117906A (en) 1990-11-27 2000-09-12 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6255345B1 (en) 1990-11-27 2001-07-03 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6262120B1 (en) 1990-11-27 2001-07-17 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6028214A (en) 1990-11-27 2000-02-22 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6291526B1 (en) 1990-11-27 2001-09-18 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6359169B1 (en) 1990-11-27 2002-03-19 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US5847151A (en) 1990-11-27 1998-12-08 Northwestern University Gaba and L-glutamic acid analogs for antiseizure treatment
US5710304A (en) 1990-11-27 1998-01-20 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US5684189A (en) 1990-11-27 1997-11-04 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US5563175A (en) 1990-11-27 1996-10-08 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US5599973A (en) 1990-11-27 1997-02-04 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US5608090A (en) 1990-11-27 1997-03-04 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6140366A (en) 1990-11-27 2000-10-31 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
US6525096B1 (en) 1990-11-27 2003-02-25 Northwestern University GABA and L-glutamic acid analogs for antiseizure treatment
WO1992014443A1 (en) 1991-02-20 1992-09-03 Warner-Lambert Company Microsphere-in-oil emulsion
WO1993012811A1 (en) 1991-12-20 1993-07-08 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising growth hormone and asparagine
WO1993023383A1 (en) 1992-05-20 1993-11-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
WO1994025016A1 (en) 1993-04-23 1994-11-10 Glaxo Group Limited Novel medical use for gaba agonists
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
JPH07215863A (en) 1993-12-21 1995-08-15 Eli Lilly & Co Non-peptidotachykinin receptor antagonist
WO1995032730A1 (en) 1994-05-26 1995-12-07 Novo Nordisk A/S A pharmaceutical preparation comprising glucagon
WO1996003122A2 (en) 1994-07-27 1996-02-08 Warner-Lambert Company Use of gabapentin in the treatment of anxiety and panic
US5792796A (en) 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
WO1996011680A3 (en) 1994-10-14 1996-06-27 Glaxo Group Ltd Use of gaba agonists in the treatment of emesis
WO1996015782A1 (en) 1994-11-18 1996-05-30 The General Hospital Corporation A method for treating vascular headaches
WO1996021661A1 (en) 1995-01-12 1996-07-18 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
WO1996026929A1 (en) 1995-02-28 1996-09-06 H. Lundbeck A/S 4-aminotetrahydrobenzisoxazole or -isothiazole compounds
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
US5616793A (en) 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5629447A (en) 1995-06-02 1997-05-13 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6046353A (en) 1995-06-07 2000-04-04 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5840956A (en) 1995-06-07 1998-11-24 Warner-Lambert Company Method of making (S)-3-(Aminomethyl)-5-Methylhexanoic acid
WO1997029101A1 (en) 1996-02-07 1997-08-14 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
US5929088A (en) 1996-02-07 1999-07-27 Warner-Lambert Company Cyclic amino acids as pharmaceutical agents
US6103932A (en) 1996-03-14 2000-08-15 Warner-Lambert Company Substituted cyclic amino acids as pharmaceutical agents
US6020370A (en) 1996-03-14 2000-02-01 Warner-Lambert Company Bridged cyclic amino acids as pharmaceutical agents
WO1997039768A1 (en) 1996-04-24 1997-10-30 Novo Nordisk A/S A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
US5998435A (en) 1996-06-26 1999-12-07 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
CA2265615C (en) 1996-09-18 2007-01-30 Astra Aktiebolag Reflux inhibitors
WO1998058641A1 (en) 1997-06-25 1998-12-30 Warner-Lambert Company Use of gaba analogs such as gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6887902B2 (en) 1997-06-25 2005-05-03 Warner-Lambert Company Anti-inflammatory method using gamma-aminobutyric acid (GABA) analogs
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6566400B1 (en) 1997-08-19 2003-05-20 Pfizer Inc. Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
US6242488B1 (en) 1997-08-20 2001-06-05 University Of Oklahoma Method for preventing and treating pain
US6426368B2 (en) 1997-08-20 2002-07-30 Warner-Lambert Company Method for preventing and treating alcoholism
US6942876B2 (en) 1997-09-08 2005-09-13 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6593368B2 (en) 1997-09-08 2003-07-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6521650B1 (en) 1997-12-16 2003-02-18 Pfizer, Inc. Amines as pharmaceutical agents
US7309719B1 (en) 1998-05-15 2007-12-18 Warner Lambert Company, Llc Stabilized pharmaceutical preparation of gamma-aminobutyric acid derivatives and process for preparing the same
US20090156677A1 (en) 1998-05-15 2009-06-18 Pfizer Inc Gabapentin-containing Solid Compositions and Process for Preparing the Same
WO1999059572A8 (en) 1998-05-15 2000-12-21 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
WO1999059573A9 (en) 1998-05-15 2000-05-04 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6326374B1 (en) 1998-07-09 2001-12-04 Warner-Lambert Company Compositions comprising GABA analogs and caffeine
US20030045500A1 (en) 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
US6306910B1 (en) 1998-07-09 2001-10-23 Warner-Lambert Company Use of Gaba-analogues for treating insomnia
US6359005B1 (en) 1998-10-16 2002-03-19 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
WO2000061234A1 (en) 1999-04-09 2000-10-19 Warner-Lambert Company Combinations of gaba analogs and tricyclic compounds to treat depression
US6436974B1 (en) 1999-06-02 2002-08-20 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US7381747B2 (en) 1999-06-10 2008-06-03 Warner-Lambert Company Llc Alpha 2 delta ligands for post-traumatic stress disorder
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
WO2001001983A1 (en) 1999-07-02 2001-01-11 Warner-Lambert Company A synergistic combination: gabapentin and pregabalin
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
US7235363B2 (en) 1999-09-16 2007-06-26 Warner-Lambert Company Method for the screening of α2δ-1 subunit binding ligands
WO2001024792A9 (en) 1999-10-07 2002-09-06 Warner Lambert Co Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
WO2001024791A1 (en) 1999-10-07 2001-04-12 Warner-Lambert Company Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders
US6891059B2 (en) 2000-01-27 2005-05-10 Warner-Lambert Company Asymmetric synthesis of pregabalin
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US7067262B2 (en) 2000-05-16 2006-06-27 Warner Lambert Company Llc Cell line for the expression of an α2δ2 calcium channel subunit and methods of use
US6703522B2 (en) 2000-08-01 2004-03-09 Warner-Lambert Company Alkyl amino acid derivatives useful as pharmaceutical agents
US20020058706A1 (en) 2000-09-22 2002-05-16 Schrier Denis J. Method for treating asthma using pregabalin
US20020072533A1 (en) 2000-10-17 2002-06-13 Denis Schrier Method of treating cartilage damage
US20040097405A1 (en) 2000-10-17 2004-05-20 Denis Schrier Method of treating cartilage damage
US6544998B2 (en) 2000-11-30 2003-04-08 Pfizer Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
US6720348B2 (en) 2000-11-30 2004-04-13 Pfizer Inc Combination of gaba agonists and aldose reductase Inhibitors
US6750171B2 (en) 2000-12-13 2004-06-15 Warner-Lambert Company Llc Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts
US7230135B2 (en) 2000-12-13 2007-06-12 Warner Lambert Company Llc Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts
US6605745B2 (en) 2000-12-13 2003-08-12 Hoge, Ii Garrett Stewart Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts
US20040002543A1 (en) 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
US6730674B2 (en) 2001-02-28 2004-05-04 Pfizer Inc Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
US7414156B2 (en) 2001-03-19 2008-08-19 Warner Lambert Co. Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation
US6689915B2 (en) 2001-03-19 2004-02-10 Warner-Lambert Company Llc Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation
US6855849B2 (en) 2001-03-19 2005-02-15 Warner-Lambert Company Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation
US6579879B2 (en) 2001-03-30 2003-06-17 Pfizer Inc Pyridazinone aldose reductase inhibitors
US6894047B2 (en) 2001-03-30 2005-05-17 Pfizer Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6849629B2 (en) 2001-03-30 2005-02-01 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US7022678B2 (en) 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
US6596900B2 (en) 2001-04-19 2003-07-22 Pfizer Inc Fused bicyclic or tricyclic amino acids
US7256216B2 (en) 2001-05-25 2007-08-14 Warner-Lambert Company Llc Liquid pharmaceutical compositions
US20030045449A1 (en) 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US7141695B2 (en) 2002-01-25 2006-11-28 Grunenthal Gmbh Methods for producing substituted acrylic acid esters and use of the latter for producing substituted γ-amino acids
US7138542B2 (en) 2002-01-31 2006-11-21 Warner Lambert Company Method of treating tinnitus
US7026505B2 (en) 2002-01-31 2006-04-11 Warner-Lambert Company Method of treating tinnitus
US7579471B2 (en) 2002-04-08 2009-08-25 Pfizer, Inc. Tropane derivatives useful in therapy
US7217721B2 (en) 2002-04-08 2007-05-15 Pfizer, Inc. Tropane derivatives useful in therapy
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US6924377B2 (en) 2002-04-30 2005-08-02 Warner-Lambert Company Process for preparing highly functionalized γ-butyrolactams and γ-amino acids
US20040006073A1 (en) 2002-06-27 2004-01-08 Dooley David James Method of treating attention deficit hyperactivity disorder
US7138406B2 (en) 2002-07-08 2006-11-21 Pfizer, Inc. Modulators of the glucocorticoid receptor
US7553877B2 (en) 2002-07-08 2009-06-30 Pfizer, Inc. Modulators of the glucocorticoid receptor
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US7205295B2 (en) 2002-12-06 2007-04-17 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as therapeutic agents
US20040132636A1 (en) 2002-12-13 2004-07-08 Dooley David James Pharmaceutical uses for alpha2delta ligands
US20040138305A1 (en) 2002-12-13 2004-07-15 Taylor Charles Price Alpha2delta ligands for the treatment of fibromyalgia and other disorders
US20040143014A1 (en) 2002-12-13 2004-07-22 Pfizer Inc Therapeutic use of alpha-2-delta ligands
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20050004106A1 (en) 2003-05-16 2005-01-06 Pfizer Inc Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics
US7074814B2 (en) 2003-06-05 2006-07-11 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
US20050004177A1 (en) 2003-07-02 2005-01-06 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050148573A1 (en) 2003-09-03 2005-07-07 Pfizer Inc. Benzimidazolone compounds having 5-HT4 receptor agonistic activity
US20050059715A1 (en) 2003-09-12 2005-03-17 Dooley David James Combinations comprising alpha-2-delta ligands
US20050059654A1 (en) 2003-09-12 2005-03-17 Arneric Stephen P. Method for treatment of depression and anxiety disorders by combination therapy
US20050065176A1 (en) 2003-09-22 2005-03-24 Field Mark John Combinations
US20090036487A1 (en) 2003-09-22 2009-02-05 Pfizer Inc. Combinations
US7491835B2 (en) 2003-09-25 2009-02-17 Pfizer Inc Prodrugs of amino acids with affinity for the α2δ-protein
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20050171203A1 (en) 2003-12-18 2005-08-04 Pfizer Inc. Pregabalin composition
US20050182049A1 (en) 2004-01-29 2005-08-18 Pfizer Inc Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists
US20070191350A1 (en) 2004-03-08 2007-08-16 Pifizer Inc. Combinations comprising alpha-2-delta ligands
US20050228190A1 (en) 2004-03-12 2005-10-13 Jian Bao C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
US7279486B2 (en) 2004-03-29 2007-10-09 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
US7354925B2 (en) 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
US7390931B2 (en) 2004-04-01 2008-06-24 Pfizer Inc. Preparation of P-chirogenic phospholanes and their use in asymmetric synthesis
US20050222464A1 (en) 2004-04-01 2005-10-06 Hoge Garrett S Ii Preparation of P-chirogenic phospholanes and their use in asymmetric synthesis
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
US20070196905A1 (en) 2004-04-14 2007-08-23 Pfizer Inc. Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids
US20090170897A1 (en) 2004-04-20 2009-07-02 Pfizer, Inc. Method of Treating Neuropathic Pain
WO2005102389A3 (en) 2004-04-20 2006-08-17 Pfizer Prod Inc Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
WO2005102390A3 (en) 2004-04-22 2006-05-11 Pfizer Japan Inc Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US7595329B2 (en) 2004-06-15 2009-09-29 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US20050277672A1 (en) 2004-06-15 2005-12-15 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US20050283023A1 (en) 2004-06-21 2005-12-22 Shanghui Hu Preparation of pregabalin and related compounds
US7235657B2 (en) 2004-06-29 2007-06-26 Pfizer Inc. Methods for preparing P2X7 inhibitors
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
WO2006008640A1 (en) 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
US7649004B2 (en) 2004-07-23 2010-01-19 Pfizer, Inc. Pyridine derivatives
US20070191462A1 (en) 2004-09-07 2007-08-16 Pfizer Limited Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
US7598393B2 (en) 2004-11-02 2009-10-06 Pfizer Inc. Sulfonyl benzimidazole derivatives
US7214824B2 (en) 2004-11-10 2007-05-08 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
US7423054B2 (en) 2004-11-29 2008-09-09 Warner Lambert Company Llc Therapeutic pyrazolo[3,4-b]pyridines and indazoles
US7485636B2 (en) 2004-11-29 2009-02-03 Pfizer Inc. Therapeutic pyrazolo[3,4-b]pyridines and indazoles
US7589109B2 (en) 2005-02-22 2009-09-15 Pfizer Inc Oxyindole derivatives
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US7566739B2 (en) 2005-03-10 2009-07-28 Pfizer Inc. Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists
US20100035880A1 (en) 2005-03-17 2010-02-11 Pfizer Inc Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists
US7622589B2 (en) 2005-03-17 2009-11-24 Pfizer Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
US7482375B2 (en) 2005-04-20 2009-01-27 Pfizer Inc. Compounds useful in therapy
US7612226B2 (en) 2005-04-28 2009-11-03 Pfizer Inc. Amino acid derivatives
WO2006123247A3 (en) 2005-05-20 2007-04-26 Pfizer Ltd Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
US7514457B2 (en) 2005-05-31 2009-04-07 Pfizer Inc. Substituted aryloxymethyl bicyclicmethyl acetamide compounds
WO2007052125A3 (en) 2005-11-02 2007-09-07 Pfizer Prod Inc Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
US7572797B2 (en) 2005-11-04 2009-08-11 Pfizer Inc. Amino substituted pyrazine derivatives for the treatment of pain
US7425569B2 (en) 2005-11-08 2008-09-16 Pfizer Inc 1H-pyrazoles useful in therapy
US7507742B2 (en) 2005-12-02 2009-03-24 Pfizer Inc. Spirocyclic derivatives
CA2530904A1 (en) 2005-12-20 2007-06-20 John Marino Pharmaceutical agents for the treatment of pain associated with spinal cord injury
WO2007102058A1 (en) 2006-03-06 2007-09-13 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
US20090318451A1 (en) 2007-01-15 2009-12-24 Pfizer Inc. Morpholine dopamine agonists for the treatment of pain
US7598231B2 (en) 2007-02-02 2009-10-06 Pfizer, Inc. Tricyclic compound, compositions, and methods
US7547714B2 (en) 2007-02-02 2009-06-16 Pfizer, Inc. Tricyclic compounds, compositions, and methods
US20080293746A1 (en) 2007-05-01 2008-11-27 Pfizer, Inc. Combinations comprising pregabalin

Non-Patent Citations (387)

* Cited by examiner, † Cited by third party
Title
A.F. Casy; Stereochemistry and Biological Activity; (7) from Medicinal Chemistry (3rd Edition) Part 1; Editor Alfred Burger; Wiley-Interscience; Cover pages and pp. 81-107 (1970).
Allan RD et al. (1990) A New Synthesis, Resolution and in vitro Activities of(R)and (S)-(β-phenyl-GABA. Tetrahedron 46(7):2511-2524 ("Allan 1990").
Allan RD, et al. (1990) A New Synthesis, Resolution and in vitro Activities of(R)- and (S)-f3-phenylGABA. Tetrahedron 46(7): 2511-24 Allan 1990).
Allinger et al., Organic Chemistry, Chapter 6, Worth Publishers. Inc., 1971.
AM. Krstulovic, J. Pharm. & Biomed. Analysis, 6(6-8), 1988, 641-656.
AM. Krstulovic, J. Pharm. & Biomed. Analysis, Sep. 1987.
Andruskiewicz, et al., "A Convenient Synthesis of 3-Alkyl-4-aminobutanoic Acids", Synthesis, pp. 953-955, Dec. 1989.
Andruszkiewcz et al., Chemoenzymatic Synthesis of (R)- And (S)-4-Amino-3-Methylbutanoic Acids; Synthetic Comm. (1990) 20(1): 159-166.
Andruszkiewicz, et al., "A Convenient Synthesis of 3-Alkyl-4-aminobutanoic Acids", Synthesis, Journal of Synthetic Organic Chemistry (Dec. 1989) 953-955.
Andruszkiewicz, et al., "4-Amino-3-Alkylbutanoic Acids as Substrates for Gamma-Aminobutyric Acid Aminotransferase", Journal of Biological Chemistry, 265 (36), 22288-91, 1990.
Apr. 14, 2005 Declaration of Charles Taylor submitted in Japanese Application No. JP507062/98.
Armstrong and DeMond, J. Chromatogr. Sci. 22 (1984) 411-415.
Audus et al., Characteristics of the Large Neutral Amino Acid Transport System of Bovine Brain Microvessel Endothelial Cell Monolayers, Journal Of Neurochemistry (1986) 47(2):484-488.
Bartoszyk et al, Gabapentin, Current Problems In Epilepsy, New Anticonvlsant Drugs (1986) 4:147-163.
Bartusch SL et al. (1996) Clonazepam for the treatment of lancinating phantom limb pain. Clin J Pain. 12(1)59-62.
Baxter, C.F and Roberts, E.; The y-Aminobutyric Acid-a-Ketoglutaric Acid Transaminase of Beef Brain; J. Biol. Chem. (1958) 233(5): 1135-1139.
Beesley, American Laboratory (May, 1985), 78-87.
Bellioti, et al., "Structure-Activity Relationships of Pregabalin and Analogues that Target the α2σ Protein", J. Med. Chem, 48 (7), pp. 2294-2307, 2005.
Belokon YN et al., (1986) Synthesis of Enantio- and Diastero-isomerically Pure β- and y-Substituted Glutamic Acids via Glycine Condensation with Activated Olefins. J. Chem. Soc. Perkin Trans. 1:1865-1872.
Benedito MA and Leite JR (1981) Baclofen as an Anticonvulsant in Experimental Models of Convulsions, Experimental Neurology 72:346-351.
Bennett G.J., and Xie Y.K., Pain 1988; 33:87-107.
Bennett GJ (1993) An Animal Model of Neuropathic Pain: A Review, Muscle & Nerve 16:1040-1048.
Bennett GJ, Xie Y-K. A peripheral monooneuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107.
Bennett GJ. (1994) Hypotheses on the Pathogenesis of Herpes Zoster-associated Pain, Annals of Neurology vol. 35 (Suppl. )S38-S41.
Berge et al (J Pharm Sci 66:1-19, 1977). *
Berge et al., J. Pharm. Sci., 66:1-9, 1977.
Bian, et al., "Calcium Channel Alpha2-Delta Type 1 Subunit is the Major Binding Protein for Pregabalin in Neocortex, Hippocampus, . . . ", Brain Research, 1075, p. 68-80, 2006.
Blakemore, et al., "Gabapentin SAR: Toward Novel Treatment for Pain", Abstracts of Papers Americna Chemical Society, 220 (Part 1), p. MEDI 239, 2000.
Boden, P.R., Higgenbottom, M., Hill, D.R., Horwell, D.C., Hughes, J., Rees, D.C., Roberts, E., Singh, L., Suman-Chauhan, N., and Woodruff, G.N. (1993). Cholecystokinin dipeptoid antagonists: Design, synthesis and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. J. Med. Chem., 36, 552-565.
Bonica JJ (1990) The Management of Pain, 2nd ed., Lippincott Williams & Wilkins, Philadelphia.
Bopp and Kennedy, LC-GC 6(6), (1988) 514-522.
Bowsher D. (1997) The management of postherpetic neuralgia, Postgrad Med J 73:623-629.
Brennan TJ, Vandermeulen EP, Gebhart GF. Characterization of a rat model of incisional pain. Pain 1996; 64: 493-501.
Brown, J.P., Boden, O., Singh, L. and Gee, N.S. (1996). Mechanisms of action of gabapentin (Neurontin). Rev. Contem. Pharmacother., vol. 7, No. 5, 203-214.
Bryans, et al., "Gabapentin SAR-Towards Novel Treatments for Pain", Abstracts of Papers American Chemical Society, 216(1), p. MEDI 207, 1998.
Bryans, et al., "Identification of Novel Ligands for the Gabapentin Binding Site on the α2σ Subunit of a Calcium Channel and . . . ", J. Med. Chem., 41, p1838-45, 1998.
Bucklett WR (1980) Irreversible Inhibitors of GABA Transaminase Induce Antinociceptive Effects and Potentiate Morphine, Neuropharmacology 19:715-722.
Buirkle, et al., "Pregabalin Inhibits Mechanical Hyperalgesia Origination in the Musculoskeletal System", J. Society for Neuroscience Abstracts, 27(1), p. 1332, 2001.
Burger A., Medicinal Chemistry, John Wiley & Sons, 1970, pp. 81, 83.
Burger, Alfred, A Guide to the Chemical Basis of Drug Design, John Wiley & Sons, Inc., A Wiley-Interscience publication; Chapter 2 Recent Active Research Areas; (1983) 37-91.
Butterworth J, et al, Phosphate-Activated Glutaminase in Relation to Huntington's Disease and Agonal State ; J. Neurochem. (1983);41(2):440-447.
Buu et al., Biological Actions in vivo of two y-aminobutyric acid (GABA) Analogues : B-chloro Gaba and B-Phenyl Gaba ; Br. J. Pharmacol. (1974) 52 : 401-406.
CA 2,255,652 File History (including Application for Reissue filed Dec. 20, 2005).
Cahn, R.S. et al., Specification of Molecular Chirality. Angew. Chem. Internat. Edit. vol. 5 (1966) No. 4, 385-583.
Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozocin-diabetic rats: Effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996; 68: 293-9.
Campbell, et al., Clinical trial of carbamazepine in trigeminal neuralgia, J. Neuro. Neurosurg. Psychiat. (1966) 29: 265-267.
Carette S., Chronic pain syndromes, Annals of the Rheumatic Diseases 1996; 55: 497-501.
Carvajal G, et al, Anticonvulsive Action of Substances Designed as Inhibitors of y-Aminobutyric Acid-a-Ketoglutaric Acid Transaminase ; Biochem. Pharmacol. (1964) 13:1059-1069.
Cates, Lindley A. Calculation of Drug Solubilities by Pharmacy Students. American Journal of Pharmaceutical Education. vol. 45, Feb. 1981, 11-13.
Cavanaugh JM: Neural mechanisms of lumbar pain. Spine 20: 1804-1809, 1995.
Certified English Language Translation od document C63.
Certified English Language Translation of document B1.
Certified English Language Translation of document C13.
Certified English Language Translation of document C14.
Certified English Language Translation of document C16.
Certified English Language Translation of document C6.
Chadwick, Recent Advances in Epilepsy, Pedley T A, Meldrum B S, (eds.) Churchill Livingstone, New York (1991) 5: 211-222.
Cherny NI, et al. [Pharmacotherapy of cancer pain. 3. Adjuvant drugs][Article in German]Schmerz. Mar. 1995; 9(2):55-69.
Chiralpak Chiralcel HPLC columns advertisement. J. Chromatogr., 450, No. 2., 1988; 205c.
Coderre TJ Melzack R: The contribution of excitory amino acids to central sensitization and peristent nociception after formalin-induced tissue injury. J Neurosci. 12: 3665-3670, 1992.
Coderre TJ, Melzack R: The role of NMDA receptor-operated calcium channels in persistent nociception after formalin-induced tissue injury. J Neurosci. 12:3671-3675, 1992.
Coderre TJ, Yashpal K: Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. The European Journal of Neuroscience 6: 1328-1334, 1994.
Colonge et al, Preparation of 2-Pyrrolidones and y-Amino Acids, Bulletin De La Societe Chimique De France (1962) 598-603.
Crawford et al., Gabapentin as an antiepileptic drug in man, J. Neurology Neurosurgery and Psychiatry, (1987) 50:682-686.
Cronin et al.; Gas Chromatographic-Mass Spectral Analysis of the Five-Carbon beta-, y-, and sigma-Amino Alklanoic Acids, Analytical Biochemistry 124, pp. 139-149 (1982).
Cronin et al.; Gas Chromatographic-Mass Spectral Analysis of the Five-Carbon β-, y-, and σ-Amino Alklanoic Acids, Analytical Biochemistry 124, pp. 139-149 (1982).
D. W. Armstrong, Anal Chem. 59(2), 1987, 84A-91A.
Davies, "Mechanisms of Action of Antiepileptic Drugs", Seizure, 4, pp. 267-271, 1995.
Debowksi, Sybilska, and Jurczak, J. Chromatogr. 237 (1982) 303-306; Bopp and Kennedy, LC-GC 6(6), 1988 514-522.
Defeudis, "Central GABA-ergic Systems and Analgesia", Drug Dev. Res., 3, pp. 1-15, 1983.
Doherty M. and Jones A ABC of rheumatology Fibromyalgia syndrome. BMJ. Feb. 11, 1995; 310(6976): 386-389.
Dubner R, Hargreaves KM (1989) The neurobiology of pain and its modulation. Clin J Pain 5 Suppl. 2:S1-6.
Dubuisson D., Dennis, SG. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4: 161-74.
Dyck PJ et al. (1987) Diabetic Neuropathy, WB Saunders Co., Philadelphia.
Eliel, Ernest L., Sterchemistry of Chemical Compounds, International Student Edition., (McGraw Book Company Inc., 1962).
Elliott KJ (1994) Taxonomy and Mechanisms of Neuropathic Pain, Seminars in Neurology 14(3): 195-205.
English Translation of document C1.
English Translation of document C3.
EP 0934061 File History (including Opposition Document)s.
Excerpts from J.T. Baker Catalog 870C; Chiralcel OD advertisement, C&EN, Jun. 20, 1988.
Fadel A. and Salaun J (1988) Optically Active α-alkylsuccinates from the stereoselective alkylation of chiral imide enolates. Tetrahedron Letters 29(48): 6257-6260.
Field, et al. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signaled by distinct primary sensory neurons? Pain 83 (1990), 303-311.
Field, et al., "Gabapentin(Neurontin) and S-(+)-3-Isobutylgaba Represent a Novel Class of Selective Antihyperalgesic Agents", British J. Pharmacol., (1997) 121: 1513-1522.
Field, et al., "Detection of Static and Dynamic Components of Mechanical Allodynia in Rat Models of NeuropathicPain: Are They Signalled by . . . ", 83, p303-11, 1999.
Field, et al., "Evaluation of Gabapentin and S-(+)-3-Isobutylgaba in a Rat Model of Postoperative Pain", J. Pharmacol. Exp. Ther., 282 (3), pp. 1242-1246, 1997.
Field, et al., "Futher Evidence for the Role of the α2σ Subunit of Voltage Dependent Calcium Channels in Models of NeuropathicPain", Br. J. of Pharm., 131 (2), p282-86, 2000.
Field, et al., "Gabapentin (Neurontin) and S-(+)-3-Isobutylgaba Represent a Novel Class of Selective Antihyperalgesic Agents", Br. J. Parmacol., 121, pp. 1513-1522, 1997.
Field, et al., "Gabapentin and Pregabalin, but not Morphine and Amitriptyline, Block Both Static and Dynamic Components of Mechanical . . . ", Pain (Neth.), 80, p391-98, Mar. 1999.
Field, et al., "The Gabapentin Analogue 3-Methyl-Gabapentin Blocks Both Static and Dynamic Components of Mechanical Allodynia in . . . ", British J. of Pharm., 128, p235P, 1999.
Field, M.J., Day, H., Vass, C.A and Woodruff, G.N. (1992). Antagonism of alchol withdrawl effects by the selective CCKB receptor antagonist CI-988. British Association for Psychopharmacology Meeting in Cambridge, U.K., Aug. 2-7, 1992.
Field, M.J., Holloman, E.F., McCleary, S., Hughes, J., Singh, L. Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain, Journal of Pharmacology and Experimental therapeutics, 282, 1242-1246 (1997).
Field, M.J., Hughes, J., Lewis., A.S., Oles, R.J., Singh, L., Vass, C.A and Woodruff, G.N. (1991). The anxiolytic-like actions of the selective CCK-B receptor antagonist CI-988. Br. J. Pharmacol., 102, 256P.
Field, M.J., Lewis, A.S., Lloyd, S. and Singh, L. (1991). Automation of the rat elevated X-maze test of anxiety. Br. J. Pharmacol., 102, 304P.
Field, M.J., Oles, R.J., Lewis, A.S., McCleary, S., Hughes, J. and Singh, L. (1997). Gabapentin (Neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br. J. Pharmacol., (1997) 121, 1513-1522.
Fromm GH and Terrence CF (1987) Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. Neurology 37: 1725-1728 ("Fromm 1987").
Galer, "Neuropathic pain of Peripheral Origin: Advances in Pharmacologic Treatment", Neurology, 45 (Suppl. 9), pp. S17-S25, 1995.
Gee, et al., The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the alpha2 sigmaSubunit of a Calcium Channel , J Biol. Chem., (Mar. 1996) 271(10), 5768-5776.
Gee, et al., The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2 σSubunit of a Calcium Channel , J Biol. Chem., (Mar. 1996) 271(10), 5768-5776.
Gilron, et al., "Preemptive Analgesic Effects of Steroid Anesthesia with Aphaxalone in the Rat Formalin Test", Anesthesiology, 84 (3), pp. 572-579, 1996.
Goldenberg DL (1995) Fibromyalgia: why such controversy? Annals of the Rheumatic Diseases 54:3-5.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Edition, Chapter 19, Figure 19-1 (1990).
Griffin et al. (1993) Peripheral Neuropathy, 3rd ed., ("Griffin 1993").
Hammond EJ and Wilder BJ (1985) Minireview: Gamma-Vinyl GABAGen. Pharmac. 16(5):441-447.
Handley, S.L. and Singh, L. (1984). The effect of beta adrenoceptor agonists and antagonists on head-twitch in male mice. Br. J. Pharmacol., 81, 127P.
Handley, S.L. and Singh, L. (1985). Modulation of 5-hydroxytryptamine-induced head-twitch response by drugs acting at GABA and related receptors. Br. J. Pharmacol., 86, 297-303.
Handley, S.L. and Singh, L. (1986). Chronic antidepressant treatment reduces central β-adrenoceptor sensitivity in a behaviour test. Eur. J. Pharmacol. 127, 97-103.
Handley, S.L. and Singh, L. (1986). Involvement of Locus Coeruleus in the potention of the quipazine head-twitch response by diazepam and beta-adrenceptor agonists. Neuropharmacol., 25, 1315-1321.
Handley, S.L., and Singh, L. (1984). GABA modulates the head-twitch induced by L-5-HTP. Br. J. Pharmacol., 82, 340P.
Handley, S.L., and Singh, L. (1986) Neurotransmitters and shaking behaviour-more than a ‘gut-bath’ for the brain? Trends Pharmacol. Sci., 7, 324-328.
Handley, S.L., and Singh, L. (1986) The modulation of head-twitch behaviour by drugs acting on the beta-adrenoceptors. Evidence for involvement of both beta1--and beta2-adrenoceptors. Psychopharmacol.88, 320-324.
Handley, S.L., and Singh, L. (1986). GABAa agonists potentiate and baclofen antogonises the L-5-HTP head-twitch. Br. J. Pharmacol., 84, 86P.
Handley, S.L., Mithani, S. and Singh, L. (1985). Locus Coeruleus lesions do not affect diazepam- or alpha-adrenergic modulation of operant conflict. Br. J. Pharmacol., 84, 87P.
Handley, S.L., Singh, A. and Singh, L. (1986). Ritanserin reduces morphine and clonidine withdrawl ticks. Br. J. Pharmacol., 89, 647P.
Hare PE. (1988) Chiral Mobile Phases for the Enantiomeric Resolution of Amino Acids. Chromatographic Chiral Separations. (eds. Zief M. and Crane LJ.).
Hargreaves K, Dubner R, Brown F, Flores C. Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88, 1988.
Harrison, "Modulation of the GABA Receptor Complex by a Steroid Anaesthetic", Brain Res., 323, pp. 287-292, 1984.
Hayashi; The inhibitory action of beta-Hydroxy-y-Aminobutyric Acid Upon the Seizure following Stimulation of the Motor Cortex of the Dog; J. Physiol. (London) (1959) 145:570-578.
Hayashi; The inhibitory action of β-Hydroxy-y-Aminobutyric Acid Upon the Seizure following Stimulation of the Motor Cortex of the Dog; J. Physiol. (London) (1959) 145:570-578.
Hegarty A. and Portenoy RK. (1994) Pharmacotherapy of neuropathic pain. Seminars in Neurology, 14,213-224 (Hegarty & Portenoy, 1994).
Hermansson, J. Chromatogr, 269, 1983, 71-80.
Hermansson, J., et al. Direct Liquid Chromatographic Resolution of Acidic Drugs Using a Chiral a1-Acid-Glycoprotein Column(Enantiopac), J. Liq. Chromatogr., 9 (2&3), (1986) 621-639.
Hermansson, J., Resolution of Racemic Aminoalcohols({3-Blockers), Amines and Acids as Enantiomeric Derivatives Using a Chiral a1-Acid Glycoprotein Column: , J. Chromatogr., 325, 379-384 (1985).
Hernandez, et al., "A Substrate for GABA-ergic Modulation of Dental Pulp Nociceptive Transmission", J. Dental Res., 65 (Spec. Issue), p. 754, 1986.
Hill DR et al. (1993) Localization of [3H ]gabapentin to a novel site in rat brain: autoradiographic studies. European Journal of Pharmacology 244(3):303-309.
Hill DR, Suman-Chauhan N., Woodruff GN. Localization of [3H]-gabapentin to a novel site in rat brain: Autoradiographic studies. Eur. J. Pharmacol. 1993; 244: 303-9.
Hill, "Meeting Highlights Central & Peripheral Nervous Systems ( Butt 8th World Pain Congress)", Expert Opinion Invest. Drugs, 5(11), pp. 1549-1562, 1996.
Hill, D.R., Singh, L., Boden, P., Pinnock, R., Woodruff, G.N. and Hughes, J. (1992). Detection of CCK receptor subtypes in mammalian brain using selective non-peptide antagonists. In Multiple Cholecystokinin Receptors in the CNS. Edited by Dourish, C. T., Cooper, S.J., Iversen, S.D. and Iversen L.L. Oxford University Press, pp. 57-76.
Holmdahl R., Tarkowski A., Jonsson R. Involvement of macrophages and dendritic cells in synovial inflammation of collagen induced arthritis in DBA/1 mice and spontaneous arthritis in MRL/Lpr mice. Autoimmunity 1991; 8: 271-280.
Houghton AD et al., Phantom pain: natural history and association with rehabilitation Ann R Coli Surg Engl. Jan. 1994; 76(1):22-5.
Hunter JC. et al., (1997) The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol. Apr. 18, 1997;324(2-3):153-60.
Hunter, J.C. and Singh, L. (1994). Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat. Neurosci. Lett.174, 217-221.
Hunter, J.C., Atwal, P., Woodruff, G.N. and Singh, L. (1994). Differential modulation of κ and μ opoioid antinociception by the glycine/NMDA receptor agonist D-serine. Br. J. Pharmacol., 112, 1002-1003.
Iversen, et al, Psychiatry Research (1974)11:255-256.
Iversen, S.D., Oles, R.J., Singh, L. and Tricklebank, M.D. (1986). Involvement of the haloperidol-sensitive sigma recognition site in the behaviours induced in the rat by (+)SKF-10,047. Br. J. Pharmacol., 91, 340P.
Iversen, S.D., Singh, L., Oles, R.J. and Tricklebank, M.D. (1988). The behavioural effects of excitatory amino acid (EAA) antagonists. Psychopharmacol., 96, 530/112.
Iversen, S.D., Singh, L., Oles, R.J., Preston, C. and Tricklebank, M.D. (1988). Psychophamacological profile of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801. In Sigma and Phencyclidine-Like Compounds as Molecular Probes in Biology, edited by E.F. Domino and J.M. Kamenka pp. 373-382.
J.T. Baker advertisement, LC.GC 4(10), Oct. 1986.
J.T. Baker Advertisements for chiral columns, 1986 and 1988.
Jacques, J. Collet, A., and Wilen, S.H. Enantiomers, Racemates and Resolutions, Wiley, New York 1981.
Janssens de Varebeke , et al, Effect of Milacemide, A Glycinamide Derivative, on the rat Brain y-Aminobutyric Acid System ; Biochem. Pharmacol. (1983)32(18):2751-2755.
Johns, American Laboratory, 72-76 (Jan. 1987).
Johnston, "GABAA Agonists as Targets for Drug Development", Clin. Exp. Pharmacol. and Physiol., 19, pp. 73-78, 1992.
Jurna et al., Antikonvulsiva beim Nervenschmerz(Anticonvulsant agents in neuralgic pain), Abstract, Institut fur Pharmakologie und Toxikologie der Universitat des Saarlandes, W-6650, Homburg/Saar, Bundesrepublik Deutschland ; Der Schmerz (1992) 6: 146-149.
Kandel, Schwartz & Jessell (1991) Principles of Neural Science, 3rd ed.
Kaplan, "New Anticonvulsants: Schiff Bases of y-Aminobutyric Acid and y-Aminobutyramide", J. Med. Chem., (1980)23: 702-704.
Karlsson, et al; Effect of the Convulsive agent 3-mercaptopropionic acid on the levels of GABA, other amino acids and glutamate decarboxylase in different regions of the rat brain; Biochem. Pharmacol (1974) 23:3053-3061.
Kayser V., Guilbaud G. Local and remote modifications of nociceptive sensitivity during carrageenan-induced inflammation in the rat. Pain 1987; 28: 99-107.
Kendal DA et al. (1982) Comparison of the Antinociceptive Effect of y-Aminobutyric(GABA)Agonists: Evidence for a Cholinergic Involvement, J. Pharmacol. & Therap.220(3):482-487.
Kim S.H. et al., Pain 1990; 50:355-363.
Kim SH, Chung JM. An experimental model of peripheral neuropathy produced by segmented spinal nerve ligation. Pain 1992; 50: 355-63.
Kim, Yoon C. et al., Glutamic Acid Analogs. The Synthesis of 3-Alkylgutamic Acids and 4-Alkylpyroglutatmic Acids. J. Med. Chem. 1965, 8(4), 509-513.
Kloke (1991) Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients. Onkologie 14(1):40-3.
Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neuroscience Letters 1994; 169: 181-4.
Komissarov, S.I., "Non-opiate Subarachnoidal Analgesia Induced by GABA-Positive Substances", Farmakologiia, Toksikologiia Problemy Toksikologii (1985) 48(4): 54-58.
Kopelvich, "Advances in the Search for Medicinal Drugs Based on y-Aminobutyric Acid", Russian Chemical Reviews (1979) 48(7): 679-691.
Korsgaard, "Bacolfen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia", (1976) 54:17-24.
Krall, R.L., et al., Antiepileptic drug development: II.Anticonvulsant drug screening, Epilepsia (1978) 19:409-428.
Krogsgaard, et al., "GABAA Receptor Agonists, Partial Agonists and Antagonists. Design and Therapeutic Prospects", J. Med. Chem., 37(16), pp. 2489-2505, 1994.
Krogsgaard-Larsen, "Heterocyclic Analogues of GABA: Chemistry, Molecular Pharmacology and Therapeutic Areas", Progress in Medicinal Chemistry, 22, pp. 67-120, 1985.
Laird, et al., "Use of Gabapentin in the Treatment of Neuropathic Pain", Annals of Pharmacotherapy, 34, pp. 802-807, 2000.
Lapin IP et al. (1986) Antagonism of Seizures Induced by the Administration of the Endogenous Convulsant Quinolinic Acid into RatBrain Ventricles, J. Neural Transmission 65:177-185.
Lever et al (in Annual Reports in Medicinal Chemistry, vol. 19: p. 5, 1984). *
Lever et al., Annual Reports in Medicinal Chemistry (vol. 19), p. 5, 1984.
Levine JD, Fields HL, Basbaum AI. Peptides and the primary afferent nociceptor. J. Neurosci. 1993; 2273-86.
Litchfield, J.T. and Wilcoxon, F.; A simplified method of evaluating dose-effect experiments, Journal Of Pharmacology And Experimental Therapeutics (1949) 96: 99-113.
Loscher , Anticonvulsant and Biochemical Effects of Inhibitors of GABA Aminotranserase and Valproic Acid During Subchronic Treatment in Mice; Biochem. Pharmacol. (1982) 31(5):837-842.
Loscher and Schmidt, Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations, Epilepsy Research (1988) 2(3): 145-181.
Lyrica U.S. Physician Prescribing Information.
Lyrica® Product Monograph, revised Mar. 3, 2009.
Mackin, Medical and pharmacologic management of upper extremity neuropathic pain syndromes; J Hand Therapy (Apr./Jun. 1997)10(2) 96-109.
Mamdani, FS (1994) Pharmacologic management of herpes zoster and postherpetic neuralgia, Canadian Family Physician 40:321-332.
Mao et al., Gabapentin in Pain Management; Anesth Analg (2000)91 :680-7.
Mao J et al. (1993) Patterns of Increased Brain Activity Indicative of Pain in a Rat Model of Peripheral Neuropathy, The Journal of Neuroscience 13(6): 2689-2702.
March, J. Advanced Organic chemistry; Reactions, Mechanisms and Structure, McGraw-Hill Book Company, 1968.
March, J., Advanced Organic Chemistry, 3rd Edition, John Wiley & Sons, 1985; Enantiomers, Racemates and Resolutions (J. Jacques et al. eds.) pp. 378-379 (1981).
Martens J. and Bhushan R. T.I.C. enantiomeric seperation of amino acids. Int. J. Pept. Protein Res. Dec. 1989; 34(6)433-44, ("Martens 1989").
Mathew, et al., "Gabapentin in Migraine Prophylaxis: A Preliminary Open Label Study", Neurology, 46 (Suppl. 2), p. A169, 1996.
Mathew, Jacob et al., An Efficent Synthesis of 3-Amino-4-Fluorobutanoic Acid, an Inactivator of GABA Transaminase. Synthetic Communications, 15(5), 377-383 (1985).
Maurs M. et al., (1988) Resolution of alpha-substituted amino acid enantiomers by high-performance liquid chromatography after derivitization with a chiral adduct of o-pthalaldehyde. Application to glutamic acid analogues. J. Chromatogr. 25; 440:209-215 ("Maurs 1988").
Mayer & Gebhart, Basic and Clinical Aspects of Visceral Hyperalgesia, Gastroenterology 1994: 107: 271-293.
Mayer & Raybould, Role of Visceral Afferent Mechanisms in Functional Bowel Disorders, Gastroenterology 1990 89:1688-1704.
McCaffery M and Pasero P (1999) Pain: Clinical Manual (2nd ed.), Mosby, Inc., St. Louis.
McGeer et al., The GABA System and Function of the Basal Ganglia: Huntington's Disease; GABA in Nervous System Function; Roberts et al., Eds., Raven Press: New York (1976) 487-495.
McGeer, et al., GABA and Glutamate Enzymes; Glutamine, Glutamate, and GABA in the Central Nervous System; Eds Liss: New York (1983) 3-17.
McMahon SB: NGF as a mediator of inflammatory pain. Philosophical Transactions Royal Society of London 351: 431-440, 1996.
McQuay HJ (1988) Pharmacological treatment of neuralgic and neuropathic pain. Cancer Surveys, 7(1): 141-159).
McQuay HJ and Moore RA, (1997) Systematic review of outpatient services for chronic pain control, Chapter 14—Anticonvulsant Drugs, Health Technology Assessment 1997, vol. 1, No. 6: 65-74.
McQuay, et al., "Anticonvulsant Drugs for the Management of Pain: A Systematic Review", BMJ, (Oct. 1995) 311: 1047-1052.
Meldrum B and Horton R (1978) Blockade of Epileptic Resonses in the Photosensitive Baboon, Papio papio, by Two Irreversible Inhibitors of GABA-Transaminase, y-Acetylic GABA (4-Aminohex-5-yonic Acid)and y-Vinyl GABA(Amino-hex-5-enoic Acid), Psychopharmacology 59:47-50.
Meldrum, et al, Neuronal Inhibition Mediated by GABA and Patterns of Convulsions in Baboons with Photosensitive Epilepsy (Papio Papio); Epilepsy; Harris et al., Eds., Churchill Livingston (1974) 55-64.
Mellick et al., The use of gabapentin in the treatment of reflex sympathetic dystrophy and a phobic disorder. Am J Pain Manage (1995) 5(1):7-9.
Mellick, "Successful Treatment of Reflex Sympathetic Dystrophy with Gabapentin"; Am. J. Emerg. Med., (1995) 96.
Mellick, et al., "Gabapentin in the Management of Reflex Sympathetic Dystrophy"; J. Pain Symptom Management, (1995) 10 (4): 265-266.
Mellick, et al., "Reflex Sympathetic Dystrophy Treated with Gabapentin", Arch. Phys. Med. Rehabil., (1997) 78: 98-105.
Merskey, H. & Bogduk, N. (1994) Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms (2nd ed.) Seattle: IASP Press.
Miampamba, et al., "Inflammation of the colonic wall induced by formalin as a model of acute visceral pain," Pain 57 (1994) 327-334.
Moertel, et al., "Relief of Pain by Oral Medications," Analgesic Combinations, vol. 229, No. 1, Jul. 1, 1974.
Moore, K.W., Leeson, P.D., Carling, R.W., Tricklebank, M.D. and Singh, L. (1993). Anticonvulsant activity of glycine-site NMDA antagonists. 1.2-Carboxyl prodrugs of 5,7-dichlorokynurenic acid. Bioorganic& Med. Chem. Lett., 3, 61-64.
Moote CA, The prevention of postoperative pain. Can J Anaesth. Jun. 1994; (6):527-33.
Morrison, Asymmetric Synthesis, vol. 1.1. Academic Press, 1983, Chapter 6 (Pirkle and Finn).
Morteau, et al., "Experimental Colitis Alters Visceromotol Response to Colorectal Distension in Awake Rats, " Digestive Diseases and Sciences, vol. 39, No. 6 (Jun. 1994); pp. 1239-1248.
Moss, G.P., Basic Terminology of Stereochemistry. Pure & Appl. Chem. vol. 68, No. 12, 2193-2222 (1996).
Nagahisa A. et al. (1992) Non-specific activity of(±)-CP-96, 345 in models of pain and inflammation, Br. J. Pharmacol. 107:273-275.
Neurontin U.S. Physician Prescribing Information.
Neurontin® Product Monograph, revised Feb. 25, 2008.
Nicoll, "The Effect of Conformationally Restricted Amino Acid Analogues on the Frog Spinal Cord in vitro", Br. J. Pharm., (1977) 59: 303-309.
Norman, RO.C, Principles of Organic Synthesis, (Methuen Co., Ltd., 1968).
Notificacao n. * 204/09 for PI 9710536-8 (Notification Regarding the Decision to Deny Prior Approval by ANVISA on May 13, 2009) (in Portuguese).
Ochoa JL, Yarnitsky D. Mechanical hyperalgesias in neuropathic pain patients; dynamic and static subtypes. Ann. Neurol 1993; 465-72.
Okamoto, Kawashima, and Hatada, J. Chromatogr. 363 (1986) 173-186.
Oles, R., Singh, L., Hughes, J. and Woodruff, G.N. (1990). The anticonvulsant action of gabapentin involves the glycine/NMDA receptor. 20th Annual meeting Soc. for Neurosciences. St. Louis, U.S.A., 221.6.
Oles, R.J., Singh, L. and Tricklebank, M.D. (1990). Differential effects on the behavioural and anticonvulsant properties of MK-801 following repeated administration in the mouse. Br. J. Pharmacol., 99, 286P.
Olpe H, et al., Eur. J. Pharmacol 1978, 52, 133-136.
Pardridge, Strategies for Drug Delivery through the Blood Brain Barrier, Directed Drug Delivery, Borchardt, Repta and Stella, eds. Humana Press, Clifton, New Jersey, (1985) pp. 83-96.
Partridge, et al, "characterization of the Effects of Gabapentin and 3-Isobutyl-y-Aminobutyric Acid on Substance P-induced. . .", Anesthesiology, 88 (1), p196-205, 1998.
Perekalin & Zobacheva, "Synthesis Of y-Amino Acids And Pyrrolidones," J. Gen. Chem. USSR (1959) 29: 2865-2869.
Pfeifer, et al., "A Highly Successful and Novel Model for Treatment of Chronic Painful Diabetic Peripheral Neuropathy", Diabetes Care, 16 (8), pp. 1103-1115, 1993.
Phillips et al., The effects of sodium valproate on y-aminobutyrate metabolism and behaviour in naive and ethanolamine-o-sulphate pretreated rats and mice ; Biochem. Pharmacol. (1982) 31(13):2257-2261.
Pierdda et al., Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate, Journal Of Pharmacology And Experimental Therapeutics (1985) 232(3): 741-745.
Plea (response) of ANVISA and INPI relating to Brazillan patent application P19710536-8 dated Oct. 5, 2009 (date on last page) (in Portugese).
Poster presentation entitled "Successful Treatment of Reflex Sympathetic Dystrophy with Gabapentin (Neurontin)", at the 13th Annual Scientific Meeting of the American Pain Society in Miami Beach, Florida, on Nov. 10-13, 1994.
Prelog, Valdimir et al. Basic Principles of the CIP-System and Proposals for a Revision, Angew. Chem. Int. Ed. Engl. 21 (1982) 567-583.
Prescribing Information for Lyrica®.
Presentation at the Indiana Chapter RSDS [Reflex Sympathetic Dystrophy Syndrome] Symposium on Aug. 13, 1994.
Presley RW. Novel appriaches to the treatment of neuropathic pain. West J Med. 1992 Nov.; 157(5):564.
Price, B.W., Ahier, R.G., Middlemiss, D.N., Singh, L., Tricklebank, M.D., and Wong, E.H.F. (1988). In vivo labeling of the NMDA receptor channel complex by [3H]MK-801. Eur. J. Pharmacol., 158, 279-282.
Prochrom preparative HPLC advertisements LC.GC, 5(5) Aug. 1987 and LC.GC, 6(2) Feb, 1988.
Purpura et al., Structure-Activity Determinants of Pharmacological Effects of Amino Acids and Related Compounds on Central Synapses, J. Neurochem. (1959) 3:238-268.
Qian J. Brown SD, Carlton SM: Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. Brain Res 715: 51-62, 1996.
Radulovic, et al.; "The Preclinical Pharmacology, Pharmacokinetics and Toxicology of Gabapentin"; Drugs of Today, 31 (8), pp. 597-611, 1995.
Ragsdale DS, Scheuer T., Catterall WA. Frequency and voltage-dependent inhibition of type IIA Na+ expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molec. Pharmacol. 1991; 40: 756-65.
Railton, J. Chromatography, 402,371-373 (1987).
Randall L., Selitto J. A method for measurement of analgesic activity on inflamed tissue. Arch Int. Pharmacodyn, 1957; 111: 409-19.
Regis advertisement, LC.GC 4(4) Apr. 1986,
Roberts et al., GABA in Nervous System Function, Raven Press: New York, 1976 (Table of Contents only).
Rock et al., Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res. (1993) 16: 89-98.
Rogawski, et al., "Calcium α2-σ Subunit, A New Antiepileptic Drug Target", Epilepsy Res., 69(3), pp. 183-272, 2006.
Rose, et al., "Gabapentin: Pharmacology and Its Use in Pain Management", Anaesthesia, 57, pp. 451-462, 2002.
Rosner, et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States", Clin. J. Pain, (1996) 12 (1): 56-58.
S.H. Wilen, Tables of Resolving Agents and Optical resolutions, University of Notre Dame Press, 1972.
Saletu et al., "Evaluation of encephalotropic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry", Int. J. Clin. Pharmacol Ther Toxcol, (Jul. 1986) 24(7):362-373.
Samkoff LM. et al., (1997) Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabepentin. Neurology. Jul. 1997; 49(1):304-305.
Sawynok J and Dickson C (1983) Involvement of GABA in the Antinociceptive Effect of y-acetylic GABA(GAG), an Inhibitor of GABA-Transaminase, Gen. Pharmac, 14(6):603-607.
Sawynok J. (1984) gabaergic Mechanisms in Antinociception, Prog. Neuro-Psychopharmacol.& Biol. Psychiat. 8:581-586 at p. 583-584.
Sawynok, Jana, "GABAergic Mechanisms of Analgesia: An Update," Pharmacology Biochemistry and Behavior, vol. 26, pp. 463-474 (1987).
Saywell, K., Singh, L., Oles, R.J., Vass, C., Leeson, P.D., Williams, B.J. and Tricklebank, M.D. (1991). The anticonvulsant properties in the mouse of the glycine/NMDA receptor antagonist, L-687,414. Br. J. Pharmacol., 102, 66P.
Schachter, et al., "Treatment of Central Pain with Gabapentin: Case reports", J. of Epilepsy, 9(3), pp. 223-226, 1996.
Schechter, et al. Attempts to Correlate Alterations in Brain GABA Metabolism by GABA-T Inhibitors with their Anticonvulsant Effects. GABA-Biochemistry and CNS Functions. 43-57 (1979).
Schill, Wainer and Barkan, J. Chromatogr., 365 (1986) 73-88.
Schill, Wainer and Barkan, J. Liq. Chromatogr., 9(2&3), (1986) 641-666.
Schmidt RE et al. (1981) Experimental Diabetic Autonomic Neuropathy, AJP 103(2): 210-225.
Segal, et al., "Gabapentin as a Novel Treatment for Postherpetic Neuralgia", American Academy of Neurology, (1996) 46(4): 1175-1176.
Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proceedings of the National Academy of Sciences USA 91: 12013-12017, 1994.
Sepragen preparative HPLC advertisements LC.GC 4(6) Jun. 1986.
Shashoua et al., y-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of y-Aminobutyric Acid; J. Med. Chem. (1984)27:659-664.
Shimoyama, et al., "Spinal Gabapentin is Antinoceptive in the Rat Formalin Test", Society for Neuroscience Abstracts, 22, p. 1371, 1996.
Silverman et al., Substituted 4-Aminobutanoic Acids: Substrates For y-Aminobutyric Acid alpha-Ketoglutaric Acid Aminotransferase, J. Bio. Chem.(Nov. 1981) 256(22): 11565-11568.
Silverman et al., Substituted 4-Aminobutanoic Acids: Substrates For y-Aminobutyric Acid α-Ketoglutaric Acid Aminotransferase, J. Bio. Chem.(Nov. 1981) 256(22): 11565-11568.
Silverman et al., Substrate Stereospecificity and Active Site Topography of y-Aminobutyric Acid Aminotransferase for beta-Aryl-y-aminobutyric Acid Analogues, J. Bio. Chem., (1987) 262(7): 3192-3195.
Silverman et al., Substrate Stereospecificity and Active Site Topography of y-Aminobutyric Acid Aminotransferase for β-Aryl-y-aminobutyric Acid Analogues, J. Bio. Chem., (1987) 262(7): 3192-3195.
Silverman R. B., Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, vol. I and II, CRC: Boca Raton (1988).
Silverman, "4-Amino-2(substituted methyl)-2-butenoic Acids: Substrates and Potent Inhibitors of GABA Aminotransferase", J. Med. Chem., (1986)29: 764-770.
Silverman, "From Basic Science to Blockbuster Drug: The Discovery of Lyrica", Angew. Chem. Int. Ed., (2008) 47:3500-3504.
Silverman, et al., "3-Alkyl-4-aminobutyric Acids: The First Class of Anticonvulsant Agents That Activates L-Glutamic Acid Decarboxylase", J. Med. Chem., 34, p. 2295-98, 1991.
Silverman, Richard B. and Levy, Mark A. Synthesis of (S)-5-Substituted 4-Aminopentanoic Acids: A New Class of y-Aminobutyric Acid Transaminase Inactivators. J. Org. Chem. 1980, 45, 815-818.
Silverman, Richard B. et al., Inactivation of y-Aminobutyric Acid Aminotransferase by (Z)-4-Amino-2-fluorobut-2-enoic Acid. Biochemistry 1988, 27, 3285-3289.
Silverman, Richard B. From Basic Science to Blockbuster Drug: The Discovery of Lyrica. Angew. Chem. Int. Ed. 2008, 47, 3500-3504.
Simon RP et al. (1989)Clinical Neurology, Appleton & Langel , East Norwalk, CT at p. 72.
Simon RP et al., (1989) Clinical Neurology, Appleton & Lange, East Norwalk, CT, at chapters 3 and 7.
Singh, et al., "The Antiepileptic Agent Gabapentin Posseses Anxiolytic-Like and Antinociceptive Actions that are Reversed by D-Serine", Psychopharmacology, 127, pp. 1-9, 1996.
Singh, L. and Handley, S.L. (1987). Behavioural evidence for an interdependence between GABAa receptors and Beta2-adrenoceptors. Eur. J. Pharmacol., 135, 419-421.
Singh, L. Donald, A.E., Foster, A.C., Hutson, P.H., Iversen, L.L., Iversen, S.D., Kemp, J.A., Leeson, P.D., Marshall, G.R., Oles, R.J., Priestley, T., Thorn, L., Tricklebank, M.D., Vass, C.A. and Williams, B.J. (1990), Enantiomers of HA-966 (3-amino-1-hydroxpyrrolid-2-one) exhibit distinct central nervous system effects: (+) —HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (−)-HA 966 is a potent gamma-butyrolactone-like sedative, Proc. Natl. Acad. Sci., U.S.A. 87, 347-351.
Singh, L. Heaton, C.J.P., Rea, P.J. and Handley, S.L. (1986), Involvement of noradrenaline in potentiation of the head-twitch response by GABA-related drugs. Psychopharmacol.88, 315-319.
Singh, L. Oles, R. and Woodruff, G. (1990). In vivo interaction of a polyamine with the NMDA receptor. Eur. J. Pharmacol., 180, 391-392.
Singh, L., Barth, T., Rupniak, N., Tricklebank, M.D. and Iversen, S.D. (1988). The tolerance and dependance potential of FG 8205, a partial agonist at the benzodiazepine receptor. Psychopharmacol., 96, 28.33.08.
Singh, L., C.A., Hunter, J.C., Woodruff, G.N. and Hughes, J. (1990). The anticonvulsant action of CI-977, a selective kappa-opioid receptor agonist: a possible involvement of the glycine/NMDA receptor complex. Eur. J. Pharmacol., 191, 477-480.
Singh, L., E.H.F., Kesingland, A. and Tricklebank, M.D. (1990). Evidence against an involvement of the haloperidol-sensitive sigma recognition site in the discriminative stimulus properties of (+)-N-allyl-normeta30cine (+)-SKF-10,047). Br. J. Pharmacol.99, 145-151.
Singh, L., Field, M. and Woodruff, G.N. (1992). Selective CCKB but not CCKA receptor antagonists show anxiolytic-like action in the rat. British Association for Psychopharmacology Meeting in Cambridge, U.K., Aug. 2-7, 1992.
Singh, L., Field, M.F., Ferris, P., Hunter, J.C., Oles, R.J., Williams, R.G. and Woodruff, G.N. (1996). The Antiepileptic Agent Gabapentin (Neurontin) Possesses Anxiolytic-Like and Antinociceptive Actions that are Reversed by D-serine. Psychopharmacol., 127, 1-9.
Singh, L., Field, M.J., Hill, D.R, Horwell, D.C., McKnight, A.T., Roberts, E., Tang, K.W. and Woodruff, G.N. (1995). Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA1 CCKB and mixed CCKA/B receptor antagonists. Eur. J. Pharmacol., 286, 185-191.
Singh, L., Field, M.J., Hughes, J., Kuo, B.-S., Suman-Chauhan, N., Tuladhar, B.R., Wright, D.S. and Naylor, R.J. The tachykinin NK1 receptor antagonist PF 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur. J. Pharmacol., 321, 209-216 (1997).
Singh, L., Field, M.J., Hughes, J., Vass, C.A. and Woodruff, G.N. (1991). Central administration of a CCK-B receptor agonist induces anxiety. Br. J. Pharmacol., 102, 45P.
Singh, L., Field, M.J., Hunter, J.C., Oles, R.J. and Woodruff, G.N. (1996). Modulation of the in vivo actions of morphine by the mixed CCKA/B receptor antagonist PD 142898. Eur. J. Pharmacol.307, 283-289.
Singh, L., Field, M.J., Vass, C.A., Hughes, J. and Woodruff, G.N. (1992). The antagonism of benzodiazepine withdrawal effects by the selective cholecystokinin-B receptor antagonist CI-988. Br. J. Pharmacol., 105, 8-10.
Singh, L., Hughes, J., Field, M. and Woodruff, G.N.,(1992). The effects of the CCKB receptor-antagonist CI-988, on withdrawal from chronic alchol treatment. CPDD Meeting in Colorado, Jun. 20-25, 1992.
Singh, L., Lewis A.S., Field, M.J., Hughes, J. and Woodruff, G.N. (1991). Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci., U.S.A. 88, 1130-1133.
Singh, L., Menzies, R. and Tricklebank, M.D. (1990). The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor. Eur. J. Pharmacol., 186, 129-132.
Singh, L., Oles, R. and Woodruff, G.N. (1990). In vivo interaction of polyamine with the NMDA receptor. 20th Annual meeting Soc. for Neurosciences. St. Louis, U.S.A., 200.4.
Singh, L., Oles, R.J. and Tricklebank, M.D. (1990). Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex. Br. J. Pharmacol., 99, 285-288.
Singh, L., Oles, R.J. and Woodruff, G.N. (1991). The lack of sedative properties of CI-988, a selective CCKB receptor antagonist. 21st Annual Meeting Soc. For Neurosciences. New Orleans, U.S.A.
Singh, L., Oles, R.J., Field, M.J., Atwal, P. Woodruff, G.N. and Hunter, J.C., (1996). Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine. Br. J. Pharmacol., 118, 1317-1325.
Singh, L., Oles, R.J., Vass, C.A. and Woodruff, G.N. (1991). A slow intravenous infusion of N-methyl-DL-aspartate as a seizure model in the mouse. J. Neurosci. Meth., 37, 227-232.
Singh., L., Field, M.J., Hughes, J., Oles, R.J., Vass, C.A. and Woodruff, G.N. (1991). The behavioural properties of CI-988, a selective CCK-B receptor antagonist. Br. J. Pharmacol., 104, 239-245.
Sist et al., Gabapentin for idiopathic trigeminal neuralgia: report of two cases. Neurology, (1997)48: 1467-1471.
Sist et al., Gabapentin for Idiopathic Trigeminal Neuralgia; Report of Two Cases, Neurology, May 1997 48:1467.
Smith et al. (1994) Increased sensitivity to the antinociceptive activity of (+/−)-baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia. Neuropharmacology, Sep. 1994; 33(9): 1103-8.
Smith et al., Kinetics of Neutral Amino Acid Transport Across the Blood-Brain Barrier, Journal Of Neurochemistry, (1987) 49(5): 1651-1658.
Sobocinska et al.; Resolution of Racemic beta-Phenyl-y-Aminobutyric Acid Into Its Enantiomers and Determination of Their Absolute Configuration; Roczniki Chemii 48; pp. 461-465 (1974).
Sobocinska et al.; Resolution of Racemic β-Phenyl-y-Aminobutyric Acid Into Its Enantiomers and Determination of Their Absolute Configuration; Roczniki Chemii 48; pp. 461-465 (1974).
Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M: Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scandinavian Journal of Rheumatology 24: 360-365, 1995.
Sosnowski M., Pain Management: physiopathology, future research and endpoints. Support Care in Cancer 1:79-88, 1993.
Spokes, GABA in Huntington's Chorea, Parkinsonism and Schizophrenia; Adv. Exp. Med. Biol. (1978)123:461-473.
Stacey, et al., "Gabapentin and Neuropathic Pain States: A Case Series Report", Regional Anesthesia, 21 (Suppl. 2), p. 65, 1996.
Stanfa, L.C., Singh, L., Williams, R.G. and A.H. Dickenson (1997). Gabapentin (Neurontin), ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport, 8, 587-590 (1997).
Steinman et al.; Narrative Review:The Promotion of Gabapentin: An Analysis of Internal Industry Documents; Annals of Internal Medicine, 145(4), pp. 284-293 (2006).
Suman-Chauhan, et al., "Characterisation of [3H]gabapentin Binding to a Novel Site in Rat Brain; Homogenate Binding Studies", Eur. Jr. Pharmacol., (1993) 244 (3): 293-301.
Suman-Chauhan, et al., "Characterisation of [3H]Gabapentin Binding to a Novel Site in Rat Brain:Homogenate Binding Studies", Eur. J. Pharmacol., 244 (3), pp. 293-301, 1993.
Swerdlow, M. (1984) Anticonvulsant drugs and chronic pain. Clinical Neuropharmacology, 7, 51-82. (Swerdlow, 1984).
Swinyard et al., "General Principles: Experimental Selection, Qualification, and Evaluation of Anticonvulsants," Antiepileptic Drugs, Third Edition, edited by R. Levy et al., Raven Press, Ltd., New York, (1989) 85-102.
Takano S. et al., (1987) Fractional Synthesis of (R)-y-amino- β-hydroxybutanoic acid (GABOB) from (R)-epichlorohydrin, Tetrahedron Letters 28(16): 1783-1784.
Taylor, "Emerging Perspective on the Mechanism of Action of Gabapentin", Neurology, 44 (Suppl. 5), pp. S10-S16, 1994.
Taylor, "Gabapentin: Mechanisms of Action", Antiepileptic Drugs (Fourth Edition), pp. 829-841, 1995.
Taylor, "Mechanism of Action of New Anti-Epileptic Drugs", Royal Society of Medicine Inter.l Congress and Symposium Series New Trends in Epilepsy Management, 198, p. 13-40, 1993.
Taylor, "Perspectives on the Pharmacology of Gabapentin (Neurontin) and Potential Mechanism of Action", Boll. Lega. It. Epii. 86/87, pp. 51-53, 1994.
Taylor, et al, "Pharmacology and Mechanism of Action of Pregablin: The Calcium Channel α2-σ (Alpha2-Delta) Subunit as a Target . . . ", Epilepsy Res., 73, p. 137-50, 2007.
Taylor, et al., "3-Alkyl GABA and 3-Alkylglutamic Acid Analogues: Two New Classes of Anticonvulsant Agents", Epilepsy Res., (1992) 11: 103-110.
Taylor, et al., "Potent and Stereospecific Anticonvulsant Activity of 3-Isobutyl GABA Relates to in Vitro Binding at a Novel Site Labeled by Tritiated Gabapentin", Epilepsy Res., (1993)14: 11-15.
Taylor, et al., "A Summary of Mechanistic Hypothesis of Gabapentin Pharmacology", Epilepsy Research, 29, pp. 233-249, 1998.
Taylor, et al., "Pharmacology of Gabapentin, a Novel Anticonvulsant, In Vitro and in Experimental Animals", J. Epilepsia, 33 (Suppl. 3), p. 117, 1992.
Taylor, et al., "Pregabalin Inhibits Multiple Endpoints of Carrageenan Induced Pain but Not Inflammation in Rats", J. Society for Neuroscience Abstracts, 27(2), p. 1897, 2001.
Taylor, et al., Potent and Stereospecific Anticonvulsant Activity of 3-Isobutyl GABA Relates to in Vitro at a Novel Site Labeled by . . . Epilepsy Res., p. 11-15, 1993.
Taylor, Mechanisms of analgesia by gabapentin and pregabalin—Calcium channel α2-σ [Cavα2-σ]ligands, Pain 142 (2009) 13-16.
ten Hoeve, W. and Wynberg, The Design of Resolving Agents: Chiral Cyclic Phosphoric Acids. H.J. Org. Chem. 1985, 50, 4508.
Thaisrivongs S. et al., Renin Inhibitors, J. Med. Chem. 1987, 30, 976-982.
Thompson, W. J., Anderson, P.S., Britcher, S.F., Lyle, T.A., Thies, J.E. Magill, C.A., Varga, S.L., Schwering, J.E, Lyle, P.A., Christy, M.E., Evans, B.E., Colton, C.D., Holloway, M.K., Springer, J.P., Hirshfield, J.M., Ball, R.G., Amato, J.S., Larsen, R.D., Wong, E.H.F., Kemp, J.A., tricklebank, M.D., Singh, L., Oles, R.J., Priestly, T., Marshall, G.R, Knight, A.R., Middlemiss, D.N., Woodruff, G.N., and Iversen, L.L. (1990). Synthesis and pharmacological evaluation of a series of dibenzo([a,s])cycloalkenimines as N-methyl-D-aspartate antagonists. J. Med. Chem., 33, 789-808.
Thurlow, et al., "[3H]Gabapentin May Label a System-L-Like Neurtral Amino Acid Carrier in Brain", European Journal of Pharmacology, (1993)247:341-345.
Thurlow, et al., "[3H]Gabapentin May Label a System-L-Like Neutral Amino Acid Carrier in Brain", European Journal of Pharmacology, 247, pp. 341-345, 1993.
Tomson, et al., Carbamazepine in Trigeminal Neuralgia: Clinical Effects in Relation to Plasma-Concentration, Upsala J. Med. Sci., Suppl., (1980) 31: 45-46.
Translation of Written Opinion of ANVISA refusing to consent to grant of patent based on allowed Brazillian Patent Application No. P19710536-8.
Treede RD, Davis KD, Campbell JN, Raja SN: The plasticity of cutaneous hyperalgesia during sympathetic ganglion blockade in patients with neuropathic pain. Brain 115 (Pt. 2): 607-621, 1992.
Tricklebank, M.D., Bristow, L.J., Hutson, P.H., Leeson, P.D., Rowley, M.Saywell, K., Singh, L., Tattersall, F.D., Thorn, L. and Williams, B.J. (1994). The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex. Br. J. Pharmacol., 113, 729-736.
Tricklebank, M.D., Honore, T., Iversen, S.D., Kemp, J.A., Knight, A.R., Marshall, G.R., Rupniak, N.M.J., Singh, L., Tye, S., Watjen, F. and Wong, E.H.F. (1990). The pharmacological properties of the imidazobenzodiazepine, FG 8205, a novel partial agonist at the benzodiazepine receptor. Br. J. Pharmacol., 101, 753-761.
Tricklebank, M.D., Oles, R.J. and Singh, L. (1990). Reversal by inositol of the proconvulsant action of lithium in pilocarpine-treated mice. Br. J. Pharmacol., 99, 73P.
Tricklebank, M.D., Pharmacology, 1987, 299-302.
Tricklebank, M.D., Singh, L., Jackson, A. and Oles, R.J. (1991). Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Res., 558, 145-148.
Tricklebank, M.D., Singh, L., Oles, R.J., Preston, C. and Iversen, S.D. (1989). The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competively at the NMDA receptor. Eur. J. Pharmacol., 167, 127-135.
Tricklebank, M.D., Singh, L., Oles, R.J., Wong, E.H.F. and Iversen, S.D. (1987). A role for receptors of N-methyl-D-aspartic acid in the discriminative stimulus properties of phencyclidine. Eur. J. Pharmacol., 141, 497-501.
Tricklebank, M.D., Wong, E., Kemp, J., Singh, L., Rupniak, N., Woodruff, G.N., Iversen, S.D., Iversen, L.L. and Watjen, F. (1988). The Pharmacological profile of FG 8205, a partial agonist at the benzodiazepine receptor. Psychopharmacol., 96, 28.33.07.
U.S. Appl. No. 08/25,5143.
U.S. Appl. No. 08/445,398, Woodruff et al.
U.S. Appl. No. 08/924,779.
U.S. Appl. No. 10/018,616 , Brummel et al.
U.S. Appl. No. 10/089,819, Hughes et al.
U.S. Appl. No. 10/089,958 , Hughes et al.
U.S. Appl. No. 60/142,215 .
U.S. Appl. No. 60/158,271.
U.S. Appl. No. 60/559,194 .
Ueda M., Kuraishi Y., Sugimoto K., Satoh M. Evidence that glutamate is released from capsaicin-sensitive primary afferent fibers in rats: Study with on-line continuous monitoring of glutamate. Neurosci. Res. 1994; 20: 231-7.
Van, Jon, "Drug Find Worth $700 Million But Chemist Finds It a Tough Sell to Turn Over Project," Chicago Tribune, Mar. 10, 2008.
Vartanian, et al., "Activity Profile of Pregabalin in Rodent Models of Epilepsy and Ataxia", Epilepsy Res., 68, pp. 189-205, 2006.
Vaught JL et al. (1985) A Comparison of the Antinociceptive Responses to the GABA-Receptor Agonists THIP and Baclofen, Neuropharmacology 24(3):211-216.
Vinik, et al., "Recent Advances in the Diagnosis and Treatment of Diabetic Neuropathy", Endocrinologist, 6 (6), pp. 443-461, 1996.
Visceral Pain: a review of experimental studies, Pain 41: 167-234, 1990.
Volmink J. et al. Treatments for postherpetic neuralgia—a systematic review of randomized controlled trials Fam Pract. Feb. 1996; 13(1):84-91.
Wade A, Weller, PJ (1994) Handbook of Pharmaceutical Excipients2nd ed., American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Pharmaceutical Society of Great Britain.
Wainer Barkan and Schill, LC-GC 4(5), (1986) 422-430.
Wainer, Trends in Analytical Chemistry, 6, 125-134 (1987).
Waldman S D, Tutorial 28: Evaluation and Treatment of Trigeminal Neuralgia. Pain Digest (1997) 7(1):21-24.
Wang, et al., "Pharmacokinetic and Pharmacodynamic Comparison of Two Anticonvulsant Compounds, Gabapentin and Isobutyl GABA",J. Pharmaceutical Research, 12(Suppl. 9), p. S400 1995.
Weiner RS (2002) Pain Management: A Practical Guide for Clinicians (6th ed.) ("Weiner 2002").
Wetzel et al., Use of gabapentin in pain management. The Annals of Pharmacotherapy; (Sep. 1997)31: 1082-3.
Wheeler-Aceto H., Cowan A. Standarization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology 1991; 104: 35-44.
Winter CA et al. (1962) Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs.Proceedings of the Society for Experimental Biology and Medicine 111:544-547.
Witczuk B et al. (1980) 3-(p-chlorophenyl)-4-aminobutanoic acid—resolution into enantiomers and pharmacological activity. Pol. J. Pharmacol. Pharm. 32:187-196 ("Witczuk 1980").
Witczuk et al., (1978)3-(p-tolyl)-4-aminobutanoic acid, synthesis, resolution into enantiomers and pharmacological activity. Pol. J. Pharmacol. Pharmacological activity. Pol. J. Pharmacol. Pharm. 30:95-103 ("Witczuk 1978").
Wolfe F., Fibromyalgia and myofascial pain syndrome. In Portenoy RK, Kanner RM: Pain management: theory and practice, p. 145-169, Philadelphia, 1996, FA Davis.
Woodruff, G.N., Hill, D., Boden,P. , Pinnock, R., Singh, L. and Hughes, J. (1991). Functional role of brain CCK receptors. Neuropeptides, 19, (Suppl.), 45-56.
Wooley, PH. Collagen-induced arthritis in the mouse. Methods in Enzymology 1988; 162: 361-373.
Woolf CJ, Chong MS: Preemptive analgesia—treating postoperative pain by preventing the establishment of central sensitization. Anesthesia and Analgesia 77: 362-379, 1993.
Woolf CJ: A new strategy for the treatment of inflammatory pain. Prevention or elimination of central sensitization. Drugs 47 Suppl 5: 1-9; discussion 46-47, 1994.
Woolf CJ: The pathophsiology of peripheral neuropathic pain—Abnormal peripheral input and abnormal central processing. Acta Neurochirurgica 58: 125-130, 1993.
Woolf, CJ: Evidence for a central component of post-injury pain hypersensitivity. Nature 306: 686-688, 1983.
Wu et al., Abnormalities of Neurotransmitter Enzymes in Huntington's Chorea; Neurochem. Res. (1979)4(5):575-586.
Xiao and Bennett, in Gabapentin Relieves Abnormal Pains in A Rat Model Of Painful Peripheral Neuropathy, Society For Neuroscience Abstracts (1995) 21(2):356.17.
Xiao et al., Analgesia 2:267-273, 1996 (with cover page).
Xiao WH and Bennett GJ (1995) Synthetic w-Conopeptides Applied to the Site of Nerve Injury Suppress Neuropathic Pains in Rats, Journal of Pharmacology and Experimental Therapeutics 274(2):666-672.
Xiao, et al. Gabapentin Relieves Abnormal Pains in a Rat Model of Painful Peripheral Neuropathy, Soc. For Neuroscience Abstracts, 21, p. 897, 1995.
Xiao, et al., "Gabapentin Has an Antinociceptive Effect Mediated via a Spinal Site of Action in a Rat Model of Painful Peripheral Neuropathy", Analgesia, 2, pp. 267-273, 1996.
Xu XJ, Elfvin A, Wiesenfeld-Hallin Z: Subcutaneous carrageenan, but not formalin, increases the excitability of the nociceptive flexor reflex in the rat. Neuroscience Letters 196: 116-118, 1995.
Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol. & Behav. 1976; 17: 1031-6.
Yoon Kim et al.; Glutamic Acid Analogs. The Synthesis of 3-Alkylglutamic Acids and 4-Alkylpyroglutamic Acids; J. Med. Chem., 8(4), 509-513 (1965).
Yuen et al., Enantioselective Synthesis of PD144723: A Potent Stereospecific Anticonvulsant, Bioorg. Medicinal Chemistry Letters, 4 (6), pp. 823-826, 1994.
Yunus MB (1989) Fibromyalgia syndrome: new research on an old malady, BMJ 298:474-475.
Yurovskaya and Borschheva, in Psychoemotional Regulation and Labor Pain Relief During Phenibut Administration, Voprosy Okhrany Materinstava I Detstva (1990) 35(5):55-58.
Zapp, "Postpoliomyelitis Pain Treated with Gabapentin", American Family Physician, (1996) 53(8), pp. 2442 and 2445.
Zarrindast MR and Djavadan M (1988) GABAA-Antagonists and Baclofen Analgesia, Gen Pharmac. 19(5):703-706.
Zobacheva et al.; The Interaction of Nitroolefins With Malonic Dimethyl Ester; Higher Education Scientific Reports; Chemistry and Chemical Technology; No. 4; pp. 740-742 (1958).

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018143512A1 (en) 2017-02-01 2018-08-09 지엘팜텍 주식회사 High-swelling sustained-release triple tablet containing pregabalin
WO2018143511A1 (en) 2017-02-01 2018-08-09 지엘팜텍 주식회사 Oral sustained-release triple tablet containing pregabalin
US10632077B2 (en) 2017-02-01 2020-04-28 Gl Pharmtech Corp. Pregabalin-containing, oral sustained-release triple layer tablet
US11007153B2 (en) 2017-02-01 2021-05-18 Gl Pharmtech Corp. Pregabalin-containing, high swellable, sustained-release triple layer tablet

Also Published As

Publication number Publication date
NZ332762A (en) 2000-09-29
HUS1300046I1 (en) 2016-08-29
HUP9904361A2 (en) 2000-05-28
JP3693258B2 (en) 2005-09-07
EP0934061A1 (en) 1999-08-11
CA2255652A1 (en) 1998-01-29
ATE241351T1 (en) 2003-06-15
AU714980B2 (en) 2000-01-13
SI0934061T1 (en) 2003-10-31
CN1223574A (en) 1999-07-21
EP0934061B1 (en) 2003-05-28
KR100491282B1 (en) 2005-05-24
HU228426B1 (en) 2013-03-28
BR9710536A (en) 1999-08-17
EP0934061B3 (en) 2015-01-21
DE69722426T3 (en) 2015-05-07
DK0934061T6 (en) 2015-01-26
CU22850A3 (en) 2003-04-28
AU3602497A (en) 1998-02-10
NO990279L (en) 1999-01-22
WO1998003167A1 (en) 1998-01-29
PL331325A1 (en) 1999-07-05
NO990279D0 (en) 1999-01-22
IL126999A0 (en) 1999-09-22
KR20000068015A (en) 2000-11-25
CA2255652C (en) 2004-07-13
HUP9904361A3 (en) 2000-11-28
ES2200184T3 (en) 2004-03-01
DE69722426T2 (en) 2004-04-08
US6001876A (en) 1999-12-14
ZA976562B (en) 1998-02-03
DE69722426D1 (en) 2003-07-03
PT934061E (en) 2003-10-31
ES2200184T7 (en) 2015-02-10
DK0934061T3 (en) 2003-09-22
ES2200184T9 (en) 2015-03-20
NO2008018I2 (en) 2010-06-28
PL189872B1 (en) 2005-10-31
HK1021134A1 (en) 2000-06-02
NO325822B1 (en) 2008-07-21
NO2008018I1 (en) 2008-12-15
JP2000515149A (en) 2000-11-14
CN1094757C (en) 2002-11-27
IL126999A (en) 2002-03-10
HRP970387A2 (en) 1998-10-31

Similar Documents

Publication Publication Date Title
USRE41920E1 (en) Isobutylgaba and its derivatives for the treatment of pain
CA2430470C (en) Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
US20090162421A1 (en) Drugs as well as their production and use in the treatment of pain-associated neuropathies
WO2009061934A1 (en) Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
AU2007319851A1 (en) Use of gabapentin and pregabalin prodrugs for treating tinnitus
US20060264509A1 (en) Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1219624B1 (en) Remedies for neuropathic pain and model animals of neuropathic pain
CA2710318A1 (en) Drugs as well as their production and use in the treatment of pain-associated neuropathies
JP2018021023A (en) Isolated stereoisomers of (s)2-n(3-o-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide
US4540582A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
US20210220330A1 (en) Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
US20080139651A1 (en) Compounds useful for treating neurological disorders
WO2020054872A1 (en) Therapeutic agent for acute herpes zoster pain
CN117530940A (en) Application of alpha-ketoglutarate in preparation of medicines for promoting myelin repair and improving neuroinflammation

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12